Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQESGPG LVKPSETLSL TCTVSGFSLT SNDIAWIRQP PGKGLEWMGT  50
IWTDGSTNYN TAVQSRVTIS VDTSKNQFSL KLSSVTAADT AVYYCARHRL 100
YYGAFDYWGQ GTMVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT 200
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 350
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LSVTPGQPAS ISCRSSQSLE YSDGYTYLEW YLQKPGQSPQ  50
LLIYEVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQATHNP 100
YTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	145-201	259-319	365-423
	22"-95"	145"-201"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-93'	139'-199'		
	23'''-93'''	139'''-199'''		
Inter-H-L (CH1 10-CL 126)	132-219'	132"-219'''		
Inter-H-H (h 8, h 11)	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


bersacapavirum

bersacapavir — *N*-(3-cyano-4-fluorophenyl)-1-methyl-4-{[(2*S*)-1,1,1-trifluoropropan-2-yl]sulfamoyl}-1*H*-pyrrole-2-carboxamide

bersacapavir — *N*-(3-cyano-4-fluorophényl)-1-méthyl-4-{[(2*S*)-1,1,1-trifluoropropan-2-yl]sulfamoyl}-1*H*-pyrrole-2-carboxamide

bersacapavir — *N*-(3-ciano-4-fluorofenil)-1-metil-4-{[(2*S*)-1,1,1-trifluoropropan-2-il]sulfamoil}-1*H*-pirrolo-2-carboxamida

$C_{16}H_{14}F_4N_4O_3S$



bexmarilimabum #

bexmarilimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1, FELE-1, FEX1, SCARH2)], humanized monoclonal antibody;
gamma4 heavy chain humanized (1-449) [VH (*Homo sapiens* IGHV2-5*09 (91.8%) -(IGHD) -IGHJ4*01 (100%)) [10.7.14] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123-220), hinge 1-12 S10>P (230)(221-232), CH2 L1.2>E (237) (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-215')-disulfide with kappa light chain humanized (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

bexmarilimab

immunoglobuline G4-kappa, anti-[*Homo sapiens* STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1, FELE-1, FEX1, SCARH2)], anticorps monoclonal humanisé;
chaîne lourde gamma4 humanisée (1-449) [VH (*Homo sapiens* IGHV2-5*09 (91.8%) -(IGHD) - IGHJ4*01 (100%)) [10.7.14] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123-220), charnière 1-12 S10>P (230) (221-232), CH2 L1.2>E (237) (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-215')-disulfure avec la chaîne légère kappa humanisée (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')];
dimère (228-228'':231-231'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

bexmarilimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1, FELE-1, FEX1, SCARH2)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 humanizada (1-449) [VH (*Homo sapiens* IGHV2-5*09 (91.8%) -(IGHD) - IGHJ4*01 (100%)) [10.7.14] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123-220), bisagra 1-12 S10>P (230) (221-232), CH2 L1.2>E (237) (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-215')-disulfuro con la cadena ligera kappa humanizada (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')];
dímero (228-228'':231-231'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVTLKESGPT LVKPTQTLTL TCSFSGFSLS TSGMGIGWIR QPPGKALEWL  50
AHIWWDDDKR YNPALKSRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARH 100
YGYDPYYAMD YWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFEGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCTASSSVS SSYLHWYQQK PGKAPKLLIY  50
RTSNLASGVP SRFSGSGSGT DYTLTISSLQ PEDFATYYCH QYHRSPPTFG 100
QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
CLSSPVTKSF NRGEC                                        215
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-97	149-205	263-323	369-427
	22''-97''	149''-205''	263''-323''	369''-427''
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'''-89'''	135'''-195'''		
Inter-H-L (CH1 10-CL 126)	136-215'	136''-215'''		
Inter-H-H (h 8, h 11)	228-228''	231-231''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


bomedemstatum

bomedemstat — *N*-[(2*S*)-5-{[(1*R*,2*S*)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1*H*-1,2,3-triazol-1-yl)benzamide

bomédemstat — *N*-[(2*S*)-5-{[(1*R*,2*S*)-2-(4-fluorophényl)cyclopropyl]amino}-1-(4-méthylpipérazin-1-yl)-1-oxopentan-2-yl]-4-(1*H*-1,2,3-triazol-1-yl)benzamide

bomedemstat — *N*-[(2*S*)-5-{[(1*R*,2*S*)-2-(4-fluorofenil)ciclopropil]amino}-1-(4-metilpiperazin-1-il)-1-oxopentan-2-il]-4-(1*H*-1,2,3-triazol-1-il)benzamida

$C_{28}H_{34}FN_7O_2$



cevostamabum #

cevostamab — immunoglobulin G1-kappa, anti-[*Homo sapiens* FCRL5 (Fc receptor like 5, FCRH5, IRTA2, BXMAS1, CD307e)] and anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)], monoclonal antibody, bispecific tetravalent;
gamma1 heavy chain anti-FCRL5 (1-450) [VH (*Mus musculus* IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/*Homo sapiens* IGHV4-4*08 (72.9%) -(IGHD) -IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14] (26-33.51-57.96-109) (1-120) -*Homo sapiens* IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain anti-FCRL5 (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
gamma1 heavy chain anti-CD3 (1"-449") [VH (*Homo sapiens* IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1"-119") -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86 (CH1 R120>K (216) (120-217), hinge 1-15 (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120"-449")], (222"-219"')-disulfide with kappa light chain anti-CD3 (1"'-219"') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (88.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1"'-112"') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113"'-219"')];
dimer (229-228":232-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells

cévostamab	immunoglobuline G1-kappa anti-[*Homo sapiens* FCRL5 (récepteur Fc like 5, FCRH5, IRTA2, BXMAS1, CD307e)] et anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)], anticorps monoclonal, bispécifique tétravalent; chaîne lourde gamma1 anti-FCRL5 (1-450) [VH (*Mus musculus* IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/*Homo sapiens* IGHV4-4*08 (72.9%) -(IGHD) -IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14] (26-33.51-57.96-109) (1-120) -*Homo sapiens* IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1 R120>K (217) (121-218), charnière 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère kappa anti-FCRL5 (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; chaîne lourde gamma1 anti-CD3 (1"-449") [VH (*Homo sapiens* IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1"-119") -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86 (CH1 R120>K (216) (120-217), charnière 1-15 (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120"-449")], (222"-219"')-disulfure avec la chaîne légère kappa anti-CD3 (1"'-219"') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (88.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1"'-112"') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113"'-219"')]; dimère (229-228":232-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO)
cevostamab	inmunoglobulina G1-kappa anti-[*Homo sapiens* FCRL5 (receptor Fc like 5, FCRH5, IRTA2, BXMAS1, CD307e)] y anti-[*Homo sapiens* CD3E (CD3 épsilon, Leu-4)], anticuerpo monoclonal, biespecífico tetravalente; cadena pesada gamma1 anti-FCRL5 (1-450) [VH (*Mus musculus* IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/*Homo sapiens* IGHV4-4*08 (72.9%) -(IGHD) -IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14] (26-33.51-57.96-109) (1-120) -*Homo sapiens* IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1 R120>K (217) (121-218), bisagra 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera kappa anti-FCRL5 (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; cadena pesada gamma1 anti-CD3 (1"-449") [VH (*Homo sapiens* IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1"-119") -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86 (CH1 R120>K (216) (120-217), bisagra 1-15 (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120"-449")], (222"-219"')-disulfuro con la cadena ligera kappa anti-CD3 (1"'-219"') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (88.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1"'-112"') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113"'-219"')]; dímero (229-228":232-231")-bisdisulfuro, producido por células ováricas de hamster chino (CHO)

Heavy chain / Chaîne lourde / Cadena pesada (anti-FCRL5)

```
EVQLVESGPG LVKPSETLSL TCTVSGFSLT RFGVHWVRQP PGKGLEWLGV   50
IWRGGSTDYN AAFVSRLTIS KDNSKNQVSL KLSSVTAADT AVYYCSNHYY  100
GSSDYALDNW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK  150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT  200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP  250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYG  300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ  350
VYTLPPSREE MTKNQVSLWC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV  400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK  450
```

Light chain / Chaîne légère / Cadena ligera (anti-FCRL5)

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVR NLVVWFQQKP GKAPKLLIYS   50
GSYRYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSPPYTFGQ  100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  200
LSSPVTKSFN RGEC                                         214
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD3)

```
EVQLVQSGAE VKKPGASVKV SCKASGFTFT SYYIHWVRQA PGQGLEWIGW   50
IYPENDNTKY NEKFKDRVTI TADTSTSTAY LELSSLRSED TAVYYCARDG  100
YSRYYFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD  150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY  200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK  250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYGS  300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV  350
YTLPPSREEM TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTPPVL  400
DSDGSFFLVS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK   449
```

Light chain / Chaîne légère / Cadena ligera (anti-CD3)

```
DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSRTRKNYLA WYQQKPGQSP   50
KLLIYWTSTR KSGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCKQSFIL  100
RTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK  150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE  200
VTHQGLSSPV TKSFNRGEC                                    219
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	147-203	264-324	370-428
	22"-96'	146"-202"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23"'-94"'	139"'-199"'		
Inter-H-L (h 5-CL 126)	223-214'	222"-219"'		
Inter-H-H (h 11, h 14)	229-228"	232-231"		

No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación:
H CH2 N84.4>G:
300, 299"

ciltacabtagenum autoleucelum #

ciltacabtagene autoleucel	autologous peripheral blood mononuclear cell (PBMC)-derived T lymphocytes transduced *ex vivo* with a non-replicating, self-inactivating (SIN) lentiviral vector encoding a chimeric antigen receptor (CAR) targeting two epitopes of the human B cell maturation antigen (BCMA) under the control of a human elongation factor 1 alpha (EF1α) promoter The coding sequence comprises a human CD8 alpha signal peptide (CD8α SP), a BCMA targeting domain consisting of two variable heavy chain-only antibodies (VHH1 and VHH2) targeting two distinct BCMA epitopes, a human CD8 alpha hinge and transmembrane domain (CD8α hinge + TM), a human CD137 cytoplasmic domain (4-1BB) and a human CD3 zeta cytoplasmic domain (CD3ζ). The vector genome contains a chimeric Rous sarcoma virus (RSV)/truncated 5'LTR and a self-inactivating 3'LTR-SIN (Δ-U3).

ciltacabtagène autoleucel	lymphocytes T autologues dérivés de cellules mononuclées du sang périphérique (PBMC) transduits *ex vivo* avec un vecteur lentiviral non-répliquant, auto-inactivant (SIN) codant pour un récepteur d'antigène chimérique (CAR) ciblant deux épitopes de l'antigène de maturation des lymphocytes B (BCMA) humains sous le contrôle d'un promoteur du facteur d'élongation 1-alpha humain (EF1α) La séquence code pour un peptide signal CD8 alpha humain (CD8α SP), un domaine ciblant le BCMA consistant en seulement la partie variable des chaînes lourdes (VHH1 and VHH2) de deux anticorps dirigés contre deux épitopes du BCMA, une charnière et un domaine transmembranaire du CD8 alpha humain, un domaine cytoplasmique du CD 137 humain (4-1BB) et un domaine cytoplasmique du CD3 zêta humain (CD3ζ). Le génome du vecteur contient en 5', une séquence LTR (terminale longue répétée) tronquée d'un virus du sarcome de Rous (RSV) chimérique et en 3', une séquence LTR-SIN (Δ-U3) auto-inactivante.
ciltacabtagén autoleucel	linfocitos T autólogos derivados de células mononucleares de sangre periférica (PBMC) transducidos *ex vivo* con un vector lentiviral no replicativo, auto inactivante (SIN), que codifica para un receptor de antígenos quimérico (CAR) dirigido a dos epítopos del antígeno de maduración de linfocitos B (BCMA) humano bajo el control de un promotor del factor de elongación 1 alfa humano (promotor EF1α) La secuencia codificante consta de un péptido señal del CD8 alfa humano, un dominio dirigido a BCMA consistente en sólo la parte variable de las cadenas pesadas (VHH1 y VHH2) de dos anticuerpos dirigidos a dos epítopos de BCMA, una bisagra y un dominio transmembrana del CD8 alfa humano, un dominio citoplásmico del CD137 humano (4-1BB) y un dominio citoplásmico del CD3 zeta humano (CD3ζ). El genoma del vector contiene un LTR 5' truncado/RSV (virus del sarcoma de Rous) quimérico y un LTR 3'-SIN auto inactivante (Δ-U3).

conendostatinum

conendostatin	L-methionyl-human endostatin [human collagen type XVIII α-1 (COL18A1) C-terminal (1572-1754)-fragment (1-183)], canonical D^{104}, R^{110}, S^{150} form, produced in *Escherichia coli*
conendostatine	L-méthionyl-endostatine humaine [fragment C-terminal (1572-1754) du collagène humain de type XVIII α-1 (COL18A1) (1-183)], forme canonique D^{104}, R^{110}, S^{150}, produit dans *Escherichia coli*
conendostatina	L-metionil-endostatina humana [fragmento C-terminal (1572-1754) del colágeno humano de tipo XVIII α-1 (COL18A1) (1-183)], forma canónica D^{104}, R^{110}, S^{150}, producido en *Escherichia coli*

Sequence / Séquence / Secuencia

```
M                                                                    0
HSHRDFQPVL HLVALNSPLS GGMRGIRGAD FQCFQQARAV GLAGTFRAFL   50
SSRLQDLYSI VRRADRAAVP IVNLKDELLF PSWEALFSGS EGPLKPGARI  100
FSFDGKDVLR HPTWPQKSVW HGSDPNGRRL TESYCETWRT EAPSATGQAS  150
SLLGGRLLGQ SAASCHHAYI VLCIENSFMT ASK                     183
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intra-chain 33-165 135-173

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
None / aucune / ninguna

cudarolimabum #

cudarolimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, ACT35, OX40, CD134)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-453) [VH (*Homo sapiens* IGHV3-30*03 (100%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 D12 (363), L14 (365) (348-452), CHS K>del (453)) (125-453)], (227-213')-disulfide with kappa light chain *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (96.8%) - IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (233-233":236-236")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
cudarolimab	immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF4 (membre 4 de la superfamille des récepteurs du facteur de nécrose tumorale, ACT35, OX40, CD134)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 *Homo sapiens* (1-453) [VH (*Homo sapiens* IGHV3-30*03 (100%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (221) (125-222), charnière 1-15 (223-237), CH2 (238-347), CH3 D12 (363), L14 (365) (348-452), CHS K>del (453)) (125-453)], (227-213')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (96.8%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (233-233":236-236")-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
cudarolimab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF4 (miembro 4 de la superfamilia de los receptores del factor de necrosis tumoral, ACT35, OX40, CD134)], anticuerpo monoclonal *Homo sapiens*;

cadena pesada gamma1 *Homo sapiens* (1-453) [VH (*Homo sapiens* IGHV3-30*03 (100%) -(IGHD) -IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (221) (125-222), bisagra 1-15 (223-237), CH2 (238-347), CH3 D12 (363), L14 (365) (348-452), CHS K>del (453)) (125-453)], (227-213')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (96.8%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (233-233'':236-236'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV  50
ISYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGR 100
PWYSETGTSA FDIWGQGTMV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPG                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCQASQDIS NYLNWYQQKP GKAPKLLIYD  50
ASNLETGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ SDHYPTFGGG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                          213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	151-207	268-328	374-432
	22''-96''	151''-207''	268''-328''	374''-432''
Intra-L (C23-C104)	23'-88'	133'-193'		
	23'''-88'''	133'''-193'''		
Inter-H-L (h 5-CL 126)	227-213'	227''-213'''		
Inter-H-H (h 11, h 14)	233-233''	236-236''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

dapatifagenum navolactibacum #

dapatifagene navolactibac

A recombinant live attenuated *Lactococcus lactis,* subspecies *cremoris* (strain MG1363), expressing a fusion protein comprising lactococcal secretion leader SSusp45 and human trefoil factor protein 1 (hTFF1), driven by the promoter from the homologous *hllA* gene (*PhllA*); the transduced gene is located in the thymidylate synthase A (*thyA*) locus which has been deleted (930102-930469).

dapatifagène navolactibac

Lactococcus lactis, sous-espèce *cremoris,* recombinante (souche MG1363), vivante atténuée exprimant une protéine de fusion consistant en le leader de sécrétion lactoccique SSusp45 et le facteur en trèfle-1 humain (hTFF1), sous le contrôle du promoteur du gène homologue *hIIA* (*PhllA*); le gène transduit est localisé sur le locus de la thymidylate synthase A (*thyA*) qui a été supprimé (930102-930469).

dapatifagén navolactibac	*Lactococcus lactis*, subespecie *cremoris* (cepa MG1363), recombinante, viva atenuada, que expresa una proteína de fusión consistente en el leader de secreción lactocócica SSusp45 y la proteína 1 del factor trébol humano (hTFF1), dirigida por el promotor del gen homólogo *hIIA* (*PhIIA*); el gen transducido se localiza en el locus de la timidilato sintasa A (thyA), que ha sido delecionado (930102-930469).
datopotamabum #	
datopotamab	immunoglobulin G1-kappa, anti-[*Homo sapiens* TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-451) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (230-230":233-233")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
datopotamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* TACSTD2 (transducteur 2 de signaux calciques associé aux tumeurs, composant membranaire du chromosome 1 marqueur de surface 1, M1S1, antigène GA7331 associé aux tumeurs gastrointestinales, protéine GA733-1 marqueur de carcinomes pancréatiques, glycoprotéine épithéliale 1, EGP-1, antigène 2 du trophoblaste, glycoprotéine Trop-2 à la surface des cellules, TROP2)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-451) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), charnière 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (230-230":233-233")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

datopotamab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* TACSTD2 (transductor 2 de señales cálcicas asociado a los tumores, componente membranario del cromosoma 1 marcador de superficie 1, M1S1, antígeno GA7331 asociado a los tumores gastrointestinales, proteína GA733-1 marcador de carcinomas pancreáticos, glicoproteína epitelial 1, EGP-1, antígeno 2 del trofoblasto, glicoproteína Trop-2 en la superficie de las células, TROP2)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 humanizada (1-451) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), bisagra 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (230-230":233-233")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT TAGMQWVRQA PGQGLEWMGW  50
INTHSGVPKY AEDFKGRVTI SADTSTSTAY LQLSSLKSED TAVYYCARSG 100
FGSSYWYFDV WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	265-325	371-429
	22"-96"	148"-204"	265"-325"	371"-429"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	224-214'	224"-214'"		
Inter-H-H (h 11, h 14)	230-230"	233-233"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
451, 451"

datopotamabum deruxtecanum #

datopotamab deruxtecan

immunoglobulin G1-kappa, anti-[*Homo sapiens* TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody conjugated to *deruxtecan*, comprising a linker and a camptothecin derivative;

	gamma1 heavy chain humanized (1-451) [VH (*Homo sapiens* IGHV1-3*01(79.6%) -(IGHD) - IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (230-230":233-233")-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, glycoform alfa, conjugated, on an average of 4 cysteinyl, to *deruxtecan*, comprising a linker and a camptothecin derivative
datopotamab déruxtécan	immunoglobuline G1-kappa, anti-[*Homo sapiens* TACSTD2 (transducteur 2 de signaux calciques associé aux tumeurs, composant membranaire du chromosome 1 marqueur de surface 1, M1S1, antigène GA7331 associé aux tumeurs gastrointestinales, protéine GA733-1 marqueur de carcinomes pancréatiques, glycoprotéine épithéliale 1, EGP-1, antigène 2 du trophoblaste, glycoprotéine Trop-2 à la surface des cellules, TROP2)], anticorps monoclonal humanisé conjugué au *déruxtécan*, comprenant un linker et un dérivé de la camptothécine; chaîne lourde gamma1 humanisée (1-451) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) - IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), charnière 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (230-230":233-233")-bisdisulfure; produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa, conjugué sur une moyenne de 4 cystéines au *déruxtécan*, comprenant un linker et un dérivé de la camptothécine
datopotamab deruxtecán	inmunoglobulina G1-kappa, anti-[*Homo sapiens* TACSTD2 (transductor 2 de señales cálcicas asociado a los tumores, componente membrana del cromosoma 1 marcador de superficie 1, M1S1, antígeno GA7331 asociado a los tumores gastrointestinales, proteína GA733-1 marcador de carcinomas pancreáticos, glicoproteína epitelial 1, EGP-1, antígeno 2 del trofoblasto, glicoproteína Trop-2 en la superficie de las células, TROP2)], anticuerpo monoclonal humanizado conjugado con *deruxtecán*, que comprende un enlace y un derivado de la camptotecina;

cadena pesada gamma1 humanizada (1-451) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), bisagra 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (230-230":233-233")-bisdisulfuro; producido por células ováricas de hamster chino (CHO), forma glicosilada alfa, conjugado con una media de 4 cisteinas al *deruxtecán*, que comprende un enlace y un derivado de la camptotecina.

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT TAGMQWVRQA PGQGLEWMGW  50
INTHSGVPKY AEDFKGRVTI SADTSTSTAY LQLSSLKSED TAVYYCARSG 100
FGSSYWYFDV WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro


Intra-H (C23-C104)	22-96	148-204	265-325	371-429
	22"-96"	148"-204"	265"-325"	371"-429"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)*	224-214'	224"-214'"		
Inter-H-H (h 11, h 14)*	230-230"	233-233"		

*The four inter-chain disulfide bridges are not present, an average of 4 cysteinyl being conjugated each via a thioether bond to a drug linker.
*Les quatre ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
*Faltan los cuatro puentes disulfuro inter-catenarios, una media de 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

C-terminal lysine clipping:
H CHS K2:
451, 451"

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales



demupitamabum #

demupitamab	immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-449) [VH (*Homo sapiens* IGHV4-61*01 (89.9%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53-59.98-108) (1-119) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K (448-449)) (120-449)], (222-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (94.7%) - IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
démupitamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal humanisé; chaîne lourde gamma1 *Homo sapiens* (1-449) [VH (*Homo sapiens* IGHV4-61*01 (89.9%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53-59.98-108) (1-119) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (216) (120-217), charnière 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K (448-449)) (120-449)], (222-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228":231-231")-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
demupitamab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erb-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal humanizado; cadena pesada gamma1 *Homo sapiens* (1-449) [VH (*Homo sapiens* IGHV4-61*01 (89.9%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53-59.98-108) (1-119) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (216) (120-217), bisagra 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K (448-449)) (120-449)], (222-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228":231-231")-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSETLSL TCTVSGGSVS SGDYYWTWIR QSPGKGLEWI  50
GHIYYSGNTN YNPSLKSRLT ISIDTSKTQF SLKLSSVTAA DTAIYYCVRD 100
RVTGAFDIWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPST LSASVGDRVT ITCQASQDIS NYLNWYQQKP GKAPKLLIYD  50
ASNLETGVPS RFSGSGSGTD FTFTISSLQP EDIATYFCQH FDHLPLAFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-97	146-202	263-323	369-427
	22"-97"	146"-202"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	222-214'	222"-214'"		
Inter-H-H (h 11, h 14)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

docaravimabum #

docaravimab	immunoglobulin G2B-kappa, anti-[rabies virus strain ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III], *Mus musculus* monoclonal antibody; gamma2b heavy chain *Mus musculus* (1-455) [VH (*Mus musculus* IGHV2-6-7*01 (92.8%) -(IGHD) - IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51-57.96-108) (1-119) -*Mus musculus* IGHG2B*02 (CH1 (120-216), hinge 1-22 (217-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (120-455)], (134-214')-disulfide with kappa light chain *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV10-96*01 (93.7%) - IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.99-107) (1'-106') -*Mus musculus* IGKC*01 (100%) (108'-214')]; dimer (228-228":231-231":234-234":237-237")-tetrakisdisulfide, produced in mouse myeloma cell line SP2/0-Ag14, glycoform alfa
docaravimab	immunoglobuline G2B-kappa, anti-[ectodomaine épitope G-III glycoprotéine du virus de la rage souche ERA (Evelyn-Rockitniki-Abelseth)], anticorps monoclonal *Mus musculus*; chaîne lourde gamma2b *Mus musculus* (1-455) [VH (*Mus musculus* IGHV2-6-7*01 (92.8%) -(IGHD) - IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51-57.96-108) (1-119) -*Mus musculus* IGHG2B*02 (CH1 (120-216), charnière 1-22 (217-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (120-455)], (134-214')-disulfure avec la chaîne légère kappa *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV10-96*01 (93.7%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.99-107) (1'-106') -*Mus musculus* IGKC*01 (100%) (108'-214')]; dimère (228-228":231-231":234-234":237-237")-tétrakisdisulfure, produite dans la lignée cellulaire de myélome murin SP2/0-Ag14, glycoforme alfa

docaravimab

inmunoglobulina G2B-kappa, anti-[ectodominio epítopo G-III glicoproteína del virus de la rabia cepa ERA (Evelyn-Rockitniki-Abelseth)], anticuerpo monoclonal *Mus musculus*; cadena pesada gamma2b *Mus musculus* (1-455) [VH (*Mus musculus* IGHV2-6-7*01 (92.8%) -(IGHD) -IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51-57.96-108) (1-119) -*Mus musculus* IGHG2B*02 (CH1 (120-216), bisagra 1-22 (217-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (120-455)], (134-214')-disulfuro con la cadena ligera kappa *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV10-96*01 (93.7%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.99-107) (1'-106') -*Mus musculus* IGKC*01 (100%) (108'-214')]; dímero (228-228":231-231":234-234":237-237")-tetrakisdisulfuro, producida en la línea celular de mieloma murino SP2/0-Ag14, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLKESGPG LLAPSQSLSI TCTVSGFSLT GHGVNWVRQP PGKGLEWLGI  50
IWADGTTNYN SALKSRLSIS KDNSKSQVFL KMNSLQTDDT ASYYCAREGD 100
ISGYYFDYWG QGTTLTVSSA KTTPPSVYPL APGCGDTTGS SVTLGCLVKG 150
YFPESVTVTW NSGSLSSSVH TFPALLQSGL YTMSSSVTVP SSTWPSQTVT 200
CSVAHPASST TVDKKLEPSG PISTINPCPP CKECHKCPAP NLEGGPSVFI 250
FPPNIKDVLM ISLTPKVTCV VVDVSEDDPD VQISWFVNNV EVHTAQTQTH 300
REDYNSTIRV VSTLPIQHQD WMSGKEFKCK VNNKDLPSPI ERTISKIKGL 350
VRAPQVYILP PPAEQLSRKD VSLTCLVVGF NPGDISVEWT SNGHTEENYK 400
DTAPVLDSDG SYFIYSKLNM KTSKWEKTDS FSCNVRHEGL KNYYLKKTIS 450
RSPGK                                                   455
```

Light chain / Chaîne légère / Cadena ligera

```
DVQMTQTTSS LSASLGDRVT ITCRPSQDIN NYLSWYQQKP DGTVKLLIYY  50
TSRLHSGVPS RFSGSGSGTD YSLTISNLEQ EDFATYFCQQ GNTLPPTFGG 100
GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI 150
DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT 200
STSPIVKSFN RNEC                                         214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	146-201	269-329	375-433
	22"-95"	146"-201"	269"-329"	375"-433"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 11-CL 126)		134-214'	134"-214'"	
Inter-H-H (h 12, h 15, h 18, h 21)	228-228"	231-231"	234-234"	237-237"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
305, 305"
Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

ebopiprantum

ebopiprant

(3*S*)-3-[(2*S*)-3-([1,1'-biphenyl]-4-sulfonyl)-1,3-thiazolidine-2-carboxamido]-3-(4-fluorophenyl)propyl L-valinate


ébopiprant

L-valinate de (3*S*)-3-[(2*S*)-3-([1,1'-biphényl]-4-sulfonyl)-1,3-thiazolidine-2-carboxamido]-3-(4-fluorophényl)propyle

ebopiprant

L-valinato de (3*S*)-3-[(2*S*)-3-([1,1'-bifenil]-4-sulfonil)-1,3-tiazolidina-2-carboxamido]-3-(4-fluorofenil)propilo

$C_{30}H_{34}FN_3O_5S_2$



efanesoctocogum alfa #

efanesoctocog alfa	human coagulation factor VIII (FVIII, antihemophilic factor, AHF, procoagulant component) with replaced B-domain (746-1648)-sequence [FVIII domains A1-a1-A2-a2 (1-740) and N-terminal B-domain fragment (741-745), fused via a synthetic 291-peptide linker of 24 repeating 12-peptides (4 types) (746-1033) plus tripeptide ASS (1034-1036) to the FVIII C-terminal (1649-2332)-domains a3-A3-C1-C2 (1037-1720)], fused to a human immunoglobulin G1 C-terminal K>del Fc fragment (1721-1946), (1726-663':1729-666')-bisdisulfide with the TIL3-D3-TIL4 domain-containing fragment 742-1218 of the human von Willebrand factor (1'-477') [(C^{1077}>$A^{336'}$,C^{1120}>$A^{379'}$)-mutant] fused via a synthetic 148-peptide linker of 12 repeating 12-peptides (4 types) plus tetrapeptide GASS (478'-625') to a thrombin cleavable FVIII fragment 712-743 (626'-657') [thrombin-cleavable acidic region 2 plus B3 domain (1-3)-peptide] fused to a human immunoglobulin G1 C-terminal K>del Fc fragment (658'-883'), produced in human embryonic kidney 293 (HEK293) cells, glycoform alfa
éfanésoctocog alfa	facteur de coagulation VIII humain (FVIII, facteur antihémophilique, AHF, composant procoagulant) dont le domaine B a été remplacé (746-1648) [domaines A1-a1-A2-a2 du FVIII (1-740) et fragment N-terminal du domaine B (741-745), fusionné via un peptide synthétique de 291 acides aminés, fait de 24 peptides de 12 acides aminés chacun, se répétant (4 types) (746-1033), et d'un tripeptide ASS (1034-1036), à la partie C-terminale des domaines a3-A3-C1-C2 1649-2332 du FVIII (1037-1720)], fusionné au fragment Fc C-terminal K>del de l'immunoglobuline G1 humaine (1721-1946), (1726-663':1729-666') lié par des ponts disulfure au fragment contenant le domaine TIL3-D3-TIL4 du facteur de von Willebrand humain 742-1218 (1'-477') [(C^{1077}>$A^{336'}$,C^{1120}>$A^{379'}$)-mutant] fusionné via un peptide synthétique de 148 acides aminés, fait de 12 peptides de 12 acides aminés chacun, se répétant (4 types), plus un tétrapeptide GASS (478'-625'), à un fragment du FVIII clivable par la thrombine 712-743 (626'-657') [région 2 acide clivable par la thrombine plus le (1-3)-peptide du domaine B3] fusionné au fragment Fc C-terminal K>del de l'immunoglobuline G1 humaine (658'-883'), produit dans des cellules rénales embryonnaires humaines 293 (HEK293), glycoforme alfa
efanesoctocog alfa	factor de coagulación VIII humano (FVIII, factor antihemofílico, AHF, componente procoagulante) en el dominio B reemplazado (746-1648) [dominios A1-a1-A2-a2 del FVIII (1-740) y fragmento N-terminal del dominio B (741-745), fusionado a través de un péptido sintético de 291 aminoácidos, hecho de 24 péptidos de 12 aminoácidos cada uno, que se repiten (4 tipos) (746-1033), y de un tripéptido ASS (1034-1036), con la parte C-terminal de los dominios a3-A3-C1-C2 1649-2332 del FVIII (1037-1720)], fusionado con el fragmento Fc C-terminal K>del de la inmunoglobulina G1 humana (1721-1946), (1726-663':1729-666') unido por puentes disulfuro con el fragmento que contiene el dominio TIL3-D3-TIL4 del factor de von Willebrand humano 742-1218 (1'-477') [(C^{1077}>$A^{336'}$,C^{1120}>$A^{379'}$)-mutante] fusionado a través de un péptido sintético de 148 aminoácidos, hecho de 12 péptidos de 12 aminoácidos cada uno, que se repiten (4 tipos), además un tetrapéptido GASS (478'-625'), con un fragmento del FVIII escindible por la trombina 712-743 (626'-657') [región 2 ácido escindible por la trombina además el (1-3)-péptido del dominio B3] fusionado con el fragmento Fc C-terminal K>del de la inmunoglobulina G1 humana (658'-883'), producido en las células renales embrionarias humanas 293 (HEK293), glicoforma alfa

Sequence / Séquence / Secuencia

(a) BddFVIII-Fc chain:

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV   80
YDTVVITLKN MASHPVSLHA VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD PLCLTYSYLS  160
HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR  240
SLPGLIGCHR KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL MDLGQFLLFC HISSHQHDGM  320
EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL  400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI  480
TDVRPLYSRR LPKGVKHLKD FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP LLICYKESVD  560
QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL  640
SIGAQTDFLS VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR GMTALLKVSS CDKNTGDYYE  720
DSYEDISAYL LSKNNAIEPR SFSQNGTSES ATPESGPGSE PATSGSETPG TSESATPESG PGSEPATSGS ETPGTSESAT  800
PESGPGTSTE PSEGSAPGSP AGSPTSTEEG TSESATPESG PGSEPATSGS ETPGTSESAT PESGPGSPAG SPTSTEEGSP  880
AGSPTSTEEG TSTEPSEGSA PGTSESATPE SGPGTSESAT PESGPGTSES ATPESGPGSE PATSGSETPG SEPATSGSET  960
PGSPAGSPTS TEEGTSTEPS EGSAPGTSTE PSEGSAPGSE PATSGSETPG TSESATPESG PGTSTEPSEG SAPASSEITR 1040
TTLQSDQEEI DYDDTISVEM KKEDFDIYDE DENQSPRSFQ KKTRHYFIAA VERLWDYGMS SSPHVLRNRA QSGSVPQFKK 1120
VVFQEFTDGS FTQPLYRGEL NEHLGLLGPY IRAEVEDNIM VTFRNQASRP YSFYSSLISY EEDQRQGAEP RKNFVKPNET 1200
KTYFWKVQHH MAPTKDEFDC KAWAYFSDVD LEKDVHSGLI GPLLVCHTNT LNPAHGRQVT VQEFALFFTI FDETKSWYFT 1280
ENMERNCRAP CNIQMEDPTF KENYRFHAIN GYIMDTLPGL VMAQDQRIRW YLLSMGSNEN IHSIHFSGHV FTVRKKEEYK 1360
MALYNLYPGV FETVEMLPSK AGIWRVECLI GEHLHAGMST LFLVYSNKCQ TPLGMASGHI RDFQITASGQ YGQWAPKLAR 1440
LHYSGSINAW STKEPFSWIK VDLLAPMIIH GIKTQGARQK FSSLYISQFI IMYSLDGKKW QTYRGNSTGT LMVFFGNVDS 1520
SGIKHNIFNP PIIARYIRLH PTHYSIRSTL RMELMGCDLN SCSMPLGMES KAISDAQITA SSYFTNMFAT WSPSKARLHL 1600
QGRSNAWRPQ VNNPKEWLQV DFQKTMKVTG VTTQGVKSLL TSMYVKEFLI SSSQDGHQWT LFFQNGKVKV FQGNQDSFTP 1680
VVNSLDPPLL TRYLRIHPQS WVHQIALRME VLGCEAQDLY DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT 1760
CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 1840
GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 1920
NVFSCSVMHE ALHNHYTQKS LSLSPG                                                          1946
```

(b) vWF fragment-FVIII a2-Fc chain:

```
SLSCRPPMVK LVCPADNLRA EGLECTKTCQ NYDLECMSMG CVSGCLCPPG MVRHENRCVA LERCPCFHQG KEYAPGETVK  80
IGCNTCVCRD RKWNCTDHVC DATCSTIGMA HYLTFDGLKY LFPGECQYVL VQDYCGSNPG TFRILVGNKG CSHPSVKCKK 160
RVTILVEGGE IELFDGEVNV KRPMKDETHF EVVESGRYII LLLGKALSVV WDRHLSISVV LKQTYQEKVC GLCGNFDGIQ 240
NNDLTSSNLQ VEEDPVDFGN SWKVSSQCAD TRKVPLDSSP ATCHNNIMKQ TMVDSSCRIL TSDVFQDCNK LVDPEPYLDV 320
CIYDTCSCES IGDCAAFCDT IAAYAHVCAQ HGKVVTWRTA TLCPQSCEER NLRENGYEAE WRYNSCAPAC QVTCQHPEPL 400
ACPVQCVEGC HAHCPPGKIL DELLQTCVDP EDCPVCEVAG RRFASGKKVT LNPSDPEHCQ ICHCDVVNLT CEACQEPGTS 480
ESATPESGPG SEPATSGSET PGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGTS TEPSEGSAPG SPAGSPTSTE 560
EGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGSP AGSPTSTEEG SPAGSPTSTE EGASSDKNTG DYYEDSYEDI 640
SAYLLSKNNA IEPRSFSDKT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE 720
VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP SRDELTKNQV 800
SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 880
SPG                                                                                   883
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

(a) 153-179, 248-329, 528-554, 630-711, 1220-1246, 1287-1291, 1409-1557, 1562-1714, 1761-1821, 1867-1925 (Cys-SH: 310, 692, 1388);

(b) 4'-45', 13'-41', 25'-36', 29'-64', 47'-58', 66'-88', 83'-100', 86'-95', 104'-233', 126'-268', 135'-230', 151'-158', 283'-326', 297'-321', 308'-348', 328'-334', 338'-363', 367'-410', 386'-406', 390'-402', 394'-433', 414'-427', 436'-464', 459'-474', 462'-471', 698'-758', 804'-862'

(a)-(b) intermolecular: 1726-663', 1729-666'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

N41, N239, N1198, N1506, N1797 and N94', N384', N734'

O-glycosylation sites / Sites de O-glycosylation / Posiciones de O-glicosilación

potentially each Ser and Thr in the linker peptides

746-1036 and 478'-625'

Tyr-sulfation sites / Sites de Tyr-sulfation / Posiciones de Tyr-sulfación

346, 718, 719, 723, 729, 1052, 1068 and 632', 633', 637', 643'

eflepedocokinum alfa #

eflepedocokin alfa

human interleukin 22 (IL22, cytokine Zcyto18, IL10-related T-cell-derived inducible factor, IL-TIF) (1-146), fused via a $GSG_3S(G_4S)_2$ peptide linker (147-162) to a human immunoglobulin G2 C-terminal Fc fragment (163-385), P^{269}>S-mutant S^{316}>A-variant, dimer (165-165':168-168')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

eflépédocokine alfa

interleukine 22 humaine (IL22, cytokine Zcyto18, facteur inductible dérivé des lymphocytes T lié à IL10, IL-TIF) (1-146), fusionnée via un peptide liant $GSG_3S(G_4S)_2$ (147-162) au fragment Fc C-terminal de l'immunoglobuline G2 humaine (163-385), P^{269}>S-mutant S^{366}>A-variant, dimère (165-165':168-168')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

eflepedocokina alfa

interleukina 22 humana (IL22, citoquina Zcyto18, factor inducible derivado de los linfocitos T relacionado con IL10, IL-TIF) (1-146), fusionada a través de un péptido que se une a $GSG_3S(G_4S)_2$ (147-162) con el fragmento Fc C-terminal de la inmunoglobulina G2 humana (163-385), P^{269}>S-mutante S^{366}>A-variante, dímero (165-165':168-168')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
APISSHCRLD KSNFQQPYIT NRTFMLAKEA SLADNNTDVR LIGEKLFHGV   50
SMSERCYLMK QVLNFTLEEV LFPQSDRFQP YMQEVVPFLA RLSNRLSTCH  100
IEGDDLHIQR NVQKLKDTVK KLGESGEIKA IGELDLLFMS LRNACIGSGG  150
GSGGGGSGGG GSVECPPCPA PPVAGPSVFL FPPKPKDTLM ISRTPEVTCV  200
VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV VSVLTVVHQD  250
WLNGKEYKCK VSNKGLPASI EKTISKTKGQ PREPQVYTLP PSREEMTKNQ  300
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV  350
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK                  385
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intramolecular: 7-99 56-145 199-259 305-363
7'-99' 56'-145' 199'-259' 305'-363'
intermolecular: 165-165' 168-168'

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N21, N35, N64, N235 N21', N35', N64', N235'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal
H CHS K2: 385, 385'

efmarodocokinum alfa #

efmarodocokin alfa

human interleukin 22 (IL22, cytokine Zcyto18, IL10-related T-cell-derived inducible factor, IL-TIF) (1-146), fused to a human immunoglobulin G4 C-terminal Fc fragment (147-377), S^{158}>P, N^{227}>G-mutant; dimer (156-156':159-159')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

efmarodocokine alfa

interleukine 22 humaine (IL22, cytokine Zcyto18, facteur inductible dérivé des lymphocytes lié à l'IL10, IL-TIF) (1-146), fusionnée au fragment Fc C-terminal de l'immunoglobuline G4 humaine (147-377), mutant S^{158}>P, N^{227}>G, dimère (156-156':159-159')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

efmarodocokina alfa

interleukina 22 humana (IL22, citoquina Zcyto18, IL10-relacionada factor inducible derivado de células T, IL-TIF) (1-146), fusionada con el fragmento Fc C-terminal de la inmunoglobulina G4 humana (147-377), mutante S^{158}>P, N^{227}>G, dímero (156-156':159-159')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
APISSHCRLD KSNFQQPYIT NRTFMLAKEA SLADNNTDVR LIGEKLFHGV   50
SMSERCYLMK QVLNFTLEEV LFPQSDRFQP YMQEVVPFLA RLSNRLSTCH  100
IEGDDLHIQR NVQKLKDTVK KLGESGEIKA IGELDLLFMS LRNACIRVES  150
KYGPPCPPCP APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED  200
PEVQFNWYVD GVEVHNAKTK PREEQFGSTY RVVSVLTVLH QDWLNGKEYK  250
CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK  300
GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG  350
NVFSCSVMHE ALHNHYTQKS LSLSLGK                           377
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intramolecular: 7-99 56-145 191-251 297-355
7'-99' 56'-145' 191'-251' 297'-355'
intermolecular: 156-156' 159-159'

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N21, N35, N64, N143 N21', N35', N64', N143'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal
H CHS K2: 377, 377'


eliapixantum

eliapixant — 3-(5-methyl-1,3-thiazol-2-yl)-5-{[(3*R*)-oxolan-3-yl]oxy}-*N*-{(1*R*)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide

éliapixant — 3-(5-méthyl-1,3-thiazol-2-yl)-5-{[(3*R*)-oxolan-3-yl]oxy}-*N*-{(1*R*)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}benzamide

eliapixant — 3-(5-metil-1,3-tiazol-2-il)-5-{[(3*R*)-oxolan-3-il]oxi}-*N*-{(1*R*)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamida

$C_{22}H_{21}F_3N_4O_3S$




elinzanetantum

elinzanetant — 2-[3,5-bis(trifluoromethyl)phenyl]-*N*-{4-(4-fluoro-2-methylphe-nyl)-6-[(7*S*,9a*S*)-7-(hydroxymethyl)hexahydropyrazino[2,1-*c*][1,4]oxazin-8(1*H*)-yl]pyridin-3-yl}-*N*,2-dimethylpropanamide

élinzanétant — 2-[3,5-bis(trifluorométhyl)phényl]-*N*-{4-(4-fluoro-2-méthylphényl)-6-[(7*S*,9a*S*)-7-(hydroxyméthyl)hexahydropyrazino[2,1-*c*][1,4]oxazin-8(1*H*)-yl]pyridin-3-yl}-*N*,2-diméthylpropanamide

elinzanetant — 2-[3,5-bis(trifluorometil)fenil]-*N*-{4-(4-fluoro-2-metilfenil)-6-[(7*S*,9a*S*)-7-(hidroximetil)hexahidropirazino[2,1-*c*][1,4]oxazin-8(1*H*)-il]piridin-3-il}-*N*,2-dimetilpropanamida

$C_{33}H_{35}F_7N_4O_3$




enflicoxibum

enflicoxib — *rac*-4-[(5*R*)-5-(2,4-difluorophenyl)-3-(trifluoromethyl)-4,5-dihydro-1*H*-pyrazol-1-yl]benzene-1-sulfonamide

enflicoxib — *rac*-4-[(5*R*)-5-(2,4-difluorophényl)-3-(trifluorométhyl)-4,5-dihydro-1*H*-pyrazol-1-yl]benzène-1-sulfonamide

enflicoxib — *rac*-4-[(5*R*)-5-(2,4-difluorofenil)-3-(trifluorometil)-4,5-dihidro-1*H*-pirazol-1-il]benceno-1-sulfonamida

$C_{16}H_{12}F_5N_3O_2S$



and enantiomer
et énantiomère
y enantiómero


esamisulpridum

esamisulpride — 4-amino-5-(ethanesulfonyl)-*N*-{[(2*S*)-1-ethylpyrrolidin-2-yl]methyl}-2-methoxybenzamide

ésamisulpride — 4-amino-5-(éthanesulfonyl)-*N*-{[(2*S*)-1-éthylpyrrolidin-2-yl]méthyl}-2-méthoxybenzamide

esamisulprida — 4-amino-5-(etanosulfonil)-*N*-{[(2*S*)-1-etilpirrolidin-2-il]metil}-2-metoxibenzamida

$C_{17}H_{27}N_3O_4S$



exalurenum


exaluren — 4-*O*-(2-amino-2,7-dideoxy-D-*glycero*-α-D-*gluco*-heptopyranosyl)-5-*O*-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-2-deoxy-D-streptamine

exalurène — 4-*O*-(2-amino-2,7-didésoxy-D-*glycéro*-α-D-*gluco*-heptopyranosyl)-5-*O*-(5-amino-5,6-didésoxy-α-L-talofuranosyl)-2-désoxy-D-streptamine

exalureno

4-*O*-(2-amino-2,7-didesoxi-D-*glicero*-α-D-*gluco*-heptopiranosil)-5-*O*-(5-amino-5,6-didesoxi-α-L-talofuranosil)-2-desoxi-D-estreptamina

$C_{19}H_{38}N_4O_{10}$



ezabenlimabum #

ezabenlimab

immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-446) [VH (*Homo sapiens* IGHV3-23*04 (86.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (1-120)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), hinge 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS K2>del (446)) (121-446)], (134-218')-disulfide with kappa light chain humanized (1'-218') [V-KAPPA (*Homo sapiens* IGKV3D-11*01 (79.8%) -IGKJ2*02 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (226-226":229-229")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

ézabenlimab

immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-446) [VH (*Homo sapiens* IGHV3-23*04 (86.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (1-120) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), charnière 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS K2>del (446)) (121-446)], (134-218')-disulfure avec la chaîne légère kappa humanisée (1'-218') [V-KAPPA (*Homo sapiens* IGKV3D-11*01 (79.8%) -IGKJ2*02 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (226-226":229-229")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

ezabenlimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado;

cadena pesada gamma4 humanizada (1-446) [VH (*Homo sapiens* IGHV3-23*04 (86.7%) -(IGHD) - IGHJ4*01 (100%)) [8.8.13] (1-120) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), bisagra 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS K2>del (446)) (121-446)], (134-218')-disulfuro con la cadena ligera kappa humanizada (1'-218') [V-KAPPA (*Homo sapiens* IGKV3D-11*01 (79.8%) -IGKJ2*02 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')];
dímero (226-226":229-229")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVMLVESGGG LVQPGGSLRL SCTASGFTFS KSAMSWVRQA PGKGLEWVAY  50
ISGGGGDTYY SSSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARHS 100
NVNYYAMDYW GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200
YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLG     446
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT MSCRASENID VSGISFMNWY QQKPGQAPKL  50
LIYVASNQGS GIPARFSGSG SGTDFTLTIS RLEPEDFAVY YCQQSKEVPW 100
TFGQGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	261-321	367-425
	22"-96"	147"-203"	261"-321"	367"-425"
Intra-L (C23-C104)	23'-92'	138'-198'		
	23'"-92'"	138'"-198'"		
Inter-H-L (CH1 10-CL 126)	134-218'	134"-218'"		
Inter-H-H (h 8, h 11)	226-226"	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


ezeprogindum

ezeprogind — *N*-[3-(4-{3-[bis(2-methylpropyl)amino]propyl}piperazin-1-yl)propyl]-1*H*-benzimidazol-2-amine

ézéprogind — *N*-[3-(4-{3-[bis(2-méthylpropyl)amino]propyl}pipérazin-1-yl)propyl]-1*H*-benzimidazol-2-amine

ezeprogind — *N*-[3-(4-{3-[bis(2-metilpropil)amino]propil}piperazin-1-il)propil]-1*H*-benzimidazol-2-amino

$C_{25}H_{44}N_6$



feladilimabum #

feladilimab	immunoglobulin G4-kappa, anti-[*Homo sapiens* ICOS (inducible T-cell costimulator, activation-inducible lymphocyte immunomediatory molecule, AILIM, CD278)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-448) [VH (*Homo sapiens* IGHV1-69*04 (84.7%) -(IGHD) -IGHJ6*01 (100%)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-219), hinge 1-12 S10>P (229)(220-231), CH2 L1.2>E (236) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfide with kappa light chain humanized (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
féladilimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* ICOS (costimulateur inductible du lymphocyte T, molécule immunomédiateur lymphocytaire inductible par activation, AILIM, CD278)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-448) [VH (*Homo sapiens* IGHV1-69*04 (84.7%) -(IGHD) - IGHJ6*01 (100%)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-219), charnière 1-12 S10>P (229) (220-231), CH2 L1.2>E (236) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfure avec la chaîne légère kappa humanisée (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (227-227'':230-230'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
feladilimab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* ICOS (coestimulador inducible del linfocito T, molécula inmunomediadora linfocitaria inducible para activación, AILIM, CD278)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-448) [VH (*Homo sapiens* IGHV1-69*04 (84.7%) -(IGHD) - IGHJ6*01 (100%)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-219), bisagra 1-12 S10>P (229) (220-231), CH2 L1.2>E (236) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfuro con la cadena ligera kappa humanizada (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (227-227'':230-230'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DYAMHWVRQA PGQGLEWMGL  50
ISIYSDHTNY NQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCGRNN 100
YGNYGWYFDV WGQGTTVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFEGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCSASSSVS YMHWYQQKPG QAPRLLIYDT  50
SKLASGIPAR FSGSGSGTDY TLTISSLEPE DFAVYYCFQG SGYPYTFGQG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	262-322	368-426
	22"-96"	148"-204"	262"-322"	368"-426"
Intra-L (C23-C104)	23'-87'	133'-193'		
	23'"-87'"	133'"-193'"		
Inter-H-L (CH1 10-CL 126)	135-213'	135"-213'"		
Inter-H-H (h 8, h 11)	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

felzartamabum #

felzartamab	immunoglobulin G1-lambda, anti-[*Homo sapiens* CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10)], humanized monoclonal antibody; gamma1 heavy chain (1-450) [VH (*Homo sapiens* IGHV3-30*01 (90.8%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) - *Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-212')-disulfide with lambda light chain (1'-213') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR-IMGT [6.3.10] (26-31.49-51.88-97) (1'-107') -*Homo sapiens* IGLC2*01 (100%) (108'-213')]; dimer (229-229":232-232")-bisdisulfide, produced in human cell line PER.C6, glycoform alfa
felzartamab	immunoglobuline G1-lambda, anti-[*Homo sapiens* CD38 (ADP-ribosyl cyclase 1, ADP-ribose cyclique hydrolase 1, cADPr hydrolase 1, T10)], anticorps monoclonal humanisé ; chaîne lourde gamma1 (1-450) [VH (*Homo sapiens* IGHV3-30*01 (90.8%) -(IGHD) - IGHJ4*01 (92.9%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) - *Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-212')-disulfure avec la chaîne légère lambda (1'-213') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR-IMGT [6.3.10] (26-31.49-51.88-97) (1'-107') -*Homo sapiens* IGLC2*01 (100%) (108'-213')]; dimère (229-229":232-232")-bisdisulfure, produite dans des cellules humaines PER.C6, glycoforme alfa

WHO Drug Information, Vol. 34, No. 3, 2020 **Recommended INN: List 84**

felzartamab

inmunoglobulina G1-lambda, anti-[*Homo sapiens* CD38 (ADP-ribosil ciclasa 1, ADP-ribosa cíclica hidrolasa 1, cADPr hidrolasa 1, T10)], anticuerpo monoclonal humanizado ;
cadena pesada gamma1 (1-450) [VH (*Homo sapiens* IGHV3-30*01 (90.8%) -(IGHD) - IGHJ4*01 (92.9%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (217) (121-218), bisagra 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-212')-disulfuro con la cadena ligera lambda (1'-213') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR-IMGT [6.3.10] (26-31.49-51.88-97) (1'-107') -*Homo sapiens* IGLC2*01 (100%) (108'-213')];
dímero (229-229":232-232")-bisdisulfuro, producida por células humanas PER.C6, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG LVQPGGSLRL SCAASGFTFS SYYMNWVRQA PGKGLEWVSG  50
ISGDPSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDL 100
PLVYTGFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIELTQPPSV SVAPGQTARI SCSGDNLRHY YVYWYQQKPG QAPVLVIYGD  50
SKRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQTY TGGASLVFGG 100
GTKLTVLGQP KAAPSVTLFP PSSEELQANK ATLVCLISDF YPGAVTVAWK 150
ADSSPVKAGV ETTTPSKQSN NKYAASSYLS LTPEQWKSHR SYSCQVTHEG 200
STVEKTVAPT ECS                                         213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	264-324	370-428
	22"-96"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	22'-87'	135'-194'		
	22'"-87'"	135'"-194'"		
Inter-H-L (h 5-CL 126)	223-212'	223"-212'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary PER.C6-type glycans / glycanes de type PER.C6 bi-antennaires complexes fucosylés / glicanos de tipo PER.C6 biantenarios complejos fucosilados

filapixantum

filapixant

3-{[(2*R*)-4-methylmorpholin-2-yl]methoxy}-5-(5-methyl-1,3-thiazol-2-yl)-*N*-{(1*R*)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide


filapixant

3-{[(2*R*)-4-méthylmorpholin-2-yl]méthoxy}-5-(5-méthyl-1,3-thiazol-2-yl)-*N*-{(1*R*)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}benzamide

filapixant

3-{[(2*R*)-4-metilmorfolin-2-il]metoxi}-5-(5-metil-1,3-tiazol-2-il)-*N*-{(1*R*)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamida

$C_{24}H_{26}F_3N_5O_3S$




fosciclopiroxum

fosciclopirox — [(6-cyclohexyl-4-methyl-2-oxopyridin-1(2*H*)-yl)oxy]methyl dihydrogen phosphate

fosciclopirox — dihydrogénophosphate de [(6-cyclohexyl-4-méthyl-2-oxopyridin-1(2*H*)-yl)oxy]méthyle

fosciclopirox — dihidrogenofosfato de [(6-ciclohexil-4-metil-2-oxopiridin-1(2*H*)-il)oxi]metilo

$C_{13}H_{20}NO_6P$




fosifidancitinibum

fosifidancitinib — (5-{[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino}-2-oxo-1,3-benzoxazol-3(2*H*)-yl)methyl dihydrogen phosphate

fosifidancitinib — dihydrogénophosphate de (5-{[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino}-2-oxo-1,3-benzoxazol-3(2*H*)-yl)méthyle

fosifidancitinib — dihidrogenofosfato de (5-{[2-(4-fluoro-5-metilanilino-3-metoxi)-5-metilpirimidin-4-il]amino}-2-oxo-1,3-benzoxazol-3(2*H*)-il)metilo

$C_{21}H_{21}FN_5O_7P$




genisteinum

genistein — 5,7-dihydroxy-3-(4-hydroxyphenyl)-4*H*-chromen-4-one

génistéine — 5,7-dihydroxy-3-(4-hydroxyphényl)-4*H*-chromén-4-one

genisteína — 5,7-dihidroxi-3-(4-hidroxifenil)-4*H*-cromen-4-ona

$C_{15}H_{10}O_5$



giloralimabum #

giloralimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* CD40 (tumor necrosis factor receptor super family member 5, TNFRSF5)], monoclonal antibody; gamma1 heavy chain (1-442) [VH (*Homo sapiens* IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%)) CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (209) (113-210), hinge 1-15 (211-225), CH2 V37>E (268) (226-335), CH3 E12 (351), M14 (353) (336-440), CHS (441-442)) (113-442)], (215-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (*Mus musculus* IGKV1-122*01 (89.0%) -IGKJ4*01 (91.7%)/*Homo sapiens* IGKV2-29*02 (86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (221-221":224-224")-bisdisulfide
giloralimab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CD40 (membre 5 de la superfamille des récepteurs du TNF, TNFRSF5)], anticorps monoclonal; chaîne lourde gamma1 (1-442) [VH (*Homo sapiens* IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%)) CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (209) (113-210), charnière 1-15 (211-225), CH2 V37>E (268) (226-335), CH3 E12 (351), M14 (353) (336-440), CHS (441-442)) (113-442)], (215-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA (*Mus musculus* IGKV1-122*01 (89.0% -IGKJ4*01 (91.7%)/*Homo sapiens* IGKV2-29*02 (86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (221-221":224-224")-bisdisulfure
giloralimab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD40 (miembro 5 de la superfamilia de los receptores del TNF, TNFRSF5)], anticuerpo monoclonal; cadena pesada gamma1 (1-442) [VH (*Homo sapiens* IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%)) CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (209) (113-210), bisagra 1-15 (211-225), CH2 V37>E (268) (226-335), CH3 E12 (351), M14 (353) (336-440), CHS (441-442)) (113-442)], (215-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (*Mus musculus* IGKV1-122*01 (89.0% -IGKJ4*01 (91.7%)/*Homo sapiens* IGKV2-29*02 (86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (221-221":224-224")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQESGPG LVKPSETLSL TCTVSGYSIT SNYYWNWIRQ PPGKGLEWMG  50
YIRYDGSNNY NPSLKNRVTI SRDTSKNQFS LKLSSVTAAD TAVYYCARLD 100
YWGQGTTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT 150
VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT QTYICNVNHK 200
PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEEKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK         442
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LSVTPGQPAS ISCRSSQSLE NTNGNTFLNW YLQKPGQSPQ  50
LLIYRVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQVTHVP 100
FTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	139-195	256-316	362-420
	22"-96"	139"-195"	256"-316"	362"-420"
Intra-L (C23-C104)	23'-93'	139'-199'		
	23'"-93'"	139'"-199'"		
Inter-H-L (h 5-CL 126)	215-219'	215"-219'"		
Inter-H-H (h 11, h 14)	221-221"	224-224"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
292, 292"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
442, 442"


giredestrantum

giredestrant — 3-[(1*R*,3*R*)-1-(2,6-difluoro-4-{[1-(3-fluoropropyl)azetidin-3-yl]amino}phenyl)-3-methyl-1,3,4,9-tetrahydro-2*H*-pyrido[3,4-*b*]indol-2-yl]-2,2-difluoropropan-1-ol

girédestrant — 3-[(1*R*,3*R*)-1-(2,6-difluoro-4-{[1-(3-fluoropropyl)azétidin-3-yl]amino}phényl)-3-méthyl-1,3,4,9-tétrahydro-2*H*-pyrido[3,4-*b*]indol-2-yl]-2,2-difluoropropan-1-ol

giredestrant — 3-[(1*R*,3*R*)-1-(2,6-difluoro-4-{[1-(3-fluoropropil)azetidin-3-il]amino}fenil)-3-metil-1,3,4,9-tetrahidro-2*H*-pirido[3,4-*b*]indol-2-il]-2,2-difluoropropan-1-ol

$C_{27}H_{31}F_5N_4O$




icenticaftorum

icenticaftor — 3-amino-6-methoxy-*N*-[(2*S*)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide

icenticaftor — 3-amino-6-méthoxy-*N*-[(2*S*)-3,3,3-trifluoro-2-hydroxy-2-méthylpropyl]-5-(trifluorométhyl)pyridine-2-carboxamide

icenticaftor — 3-amino-6-metoxi-*N*-[(2*S*)-3,3,3-trifluoro-2-hidroxi-2-metilpropil]-5-(trifluorometil)piridina-2-carboxamida

$C_{12}H_{13}F_6N_3O_3$




icerguastatum

icerguastat — (2*E*)-2-[(2-chlorophenyl)methylidene]hydrazine-1-carboximidamide

icerguastat — (2*E*)-2-[(2-chlorophényl)méthylidène]hydrazine-1-carboximidamide

icerguastat — (2*E*)-2-[(2-clorofenil)metilideno]hidrazina-1-carboximidamida

$C_8H_9ClN_4$




idetrexedum

idetrexed — *N*-(4-{[(6*S*)-2-(hydroxymethyl)-4-oxo-4,6,7,8-tetrahydro-1*H*-cyclopenta[*g*]quinazolin-6-yl](prop-2-yn-1-yl)amino}benzoyl)-L-γ-glutamyl-D-glutamic acid

idétrexed — acide *N*-(4-{[(6*S*)-2-(hydroxyméthyl)-4-oxo-4,6,7,8-tétrahydro-1*H*-cyclopenta[*g*]quinazolin-6-yl](prop-2-yn-1-yl)amino}benzoyl)-L-γ-glutamyl-D-glutamique

idetrexed — ácido *N*-(4-{[(6*S*)-2-(hidroximetil)-4-oxo-4,6,7,8-tetrahidro-1*H*-ciclopenta[*g*]quinazolin-6-il](prop-2-in-1-il)amino}benzoil)-L-γ-glutamil-D-glutámico

$C_{32}H_{33}N_5O_{10}$




ifidancitinibum

ifidancitinib — 5-{[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino}-1,3-benzoxazol-2(3*H*)-one

ifidancitinib — 5-{[2-(4-fluoro-3-méthoxy-5-méthylanilino)-5-méthylpyrimidin-4-yl]amino}-1,3-benzoxazol-2(3*H*)-one

ifidancitinib — 5-{[2-(4-fluoro-5-metilanilino-3-metoxi)-5-metilpirimidin-4-il]amino}-1,3-benzoxazol-2(3*H*)-ona

$C_{20}H_{18}FN_5O_3$




imaradenantum

imaradenant — 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine

imaradénant — 6-(2-chloro-6-méthylpyridin-4-yl)-5-(4-fluorophényl)-1,2,4-triazin-3-amine

imaradenant — 6-(2-cloro-6-metilpiridin-4-il)-5-(4-fluorofenil)-1,2,4-triazin-3-amina

$C_{15}H_{11}ClFN_5$




inavolisibum

inavolisib — (2*S*)-2-({2-[(4*S*)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-*d*][1,4]benzoxazepin-9-yl}amino)propenamide

inavolisib — (2*S*)-2-({2-[(4*S*)-4-(difluorométhyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-*d*][1,4]benzoxazépin-9-yl}amino)propenamide

inavolisib — (2*S*)-2-({2-[(4*S*)-4-(difluorometil)-2-oxo-1,3-oxazolidin-3-il]-5,6-dihidroimidazo[1,2-*d*][1,4]benzoxazepin-9-il}amino)propanamida

$C_{18}H_{19}F_2N_5O_4$



insulinum efsitorum alfa #

insulin efsitora alfa

human insulin B-chain (1-30) variant (Y^{16}>E, F^{25}>H, T^{27}>G, P^{28}>G, K^{29}>G, T^{30}>G) fused via a G_2SG_4 peptide linker (31-37) to human insulin A-chain (38-58) variant (I^{10}>T^{47}, Y^{14}>D^{51}, N^{21}>G^{58}) and via a $(G_4Q)_3G_5$ peptide linker (59-78) to a human immunoglobulin G2 C-terminal K>del Fc fragment (79-299), dimer (80-80':83-83')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

insuline efsitora alfa

chaîne B de l'insuline humaine (1-30) variant (Y^{16}>E, F^{25}>H, T^{27}>G, P^{28}>G, K^{29}>G, T^{30}>G) fusionné via un peptide liant G_2SG_4 (31-37) à la chaîne A de l'insuline humaine (38-58) variant (I^{10}>T^{47}, Y^{14}>D^{51}, N^{21}>G^{58}) et via un peptide liant $(G_4Q)_3G_5$ (59-78) au fragment Fc C-terminal K>del de l'immunoglobuline G2 humaine (IgG2) (79-299), dimère (80-80':83-83')-bisdisulfure, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

insulina efsitora alfa

cadena B de la insulina humana (1-30) variante (Y^{16}>E, F^{25}>H, T^{27}>G, P^{28}>G, K^{29}>G, T^{30}>G) fusionada a través de un péptido que se une G_2SG_4 (31-37) a la cadena A de la insulina humana (38-58) variante (I^{10}>T^{47}, Y^{14}>D^{51}, N^{21}>G^{58}) y a través de un péptido que se une $(G_4Q)_3G_5$ (59-78) al fragmento Fc C-terminal K>del de la inmunoglobulina G2 humana (IgG2) (79-299), dímero (80-80':83-83')-bisdisulfuro, producido por las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
FVNQHLCGSH LVEALELVCG ERGFHYGGGG GGSGGGGGIV EQCCTSTCSL   50
DQLENYCGGG GGQGGGGQGG GGQGGGGGEC PPCPAPPVAG PSVFLFPPKP  100
KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN  150
STFRVVSVLT VVHQDWLNGK EYKCKVSNKG LPAPIEKTIS KTKGQPREPQ  200
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPM  250
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG   299
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

B-A	7-44	19-57	B'-A'	7'-44'	19'-57'
A-A	43-48		A'-A'	43'-48'	
Intra-Fc	114-174	220-278	114'-174'	220'-278'	
Inter-Fc	80-80'	83-83'			

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N150, N150'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

iptacopanum

iptacopan

4-{(2*S*,4*S*)-4-ethoxy-1-[(5-methoxy-7-methyl-1*H*-indol-4-yl)methyl]piperidin-2-yl}benzoic acid


iptacopan

acide 4-{(2*S*,4*S*)-4-éthoxy-1-[(5-méthoxy-7-méthyl-1*H*-indol-4-yl)méthyl]pipéridin-2-yl}benzoïque

iptacopán

ácido 4-{(2*S*,4*S*)-4-etoxi-1-[(7-metil-5-metoxi-1*H*-indol-4-il)metil]piperidin-2-il}benzoico

$C_{25}H_{30}N_2O_4$



isecarosmabum #

isecarosmab

immunoglobulin single chain VH-VH', anti-[*Homo sapiens* ADAMTSL5 (ADAMTS like 5, THSD6, thrombospondin type I domain 6)] and anti-[*Homo sapiens* ALB (albumin, human serum albumin, HSA)], *Lama glama* and humanized monoclonal antibody, bispecific bivalent;
sc VH-VH'(1-275) [*Lama glama* VH anti-ADAMTSL5 (*Lama glama* IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01 (100%)/*Homo sapiens* IGHV3-23*04 (80.2%) -(IGHD) -IGHJ1*01 (100%) [8.8.17] (1-124)) -35-mer (GGGGS)7 linker (125-159)-humanized VH anti-ALB (*Homo sapiens* IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8] (160-275),
produced in Pichia pastoris yeast, non-glycosylated

isécarosmab

immunoglobuline single chaîne VH-VH', anti-[*Homo sapiens* ADAMTSL5 (ADAMTS like 5, thrombospondine type I domaine 6)] et anti-[*Homo sapiens* ALB (albumine, sérum albumine humaine, SAH)], anticorps monoclonal *Lama glama* et humanisé, bispécifique bivalent;
sc VH-VH' (1-275) [*Lama glama* VH anti-ADAMTSL5 (*Lama glama* IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01 (100%)/*Homo sapiens* IGHV3-23*04 (80.2%) -(IGHD) -IGHJ1*01 (100%) [8.8.17] (1-124)) -35-mer (GGGGS)7 linker (125-159)-VH humanisé anti-ALB (*Homo sapiens* IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8] (160-275),
produit dans la levure Pichia pastoris, non-glycosylé

isecarosmab

inmunoglobulina cadena simple VH-VH', anti-[*Homo sapiens* ADAMTSL5 (ADAMTS like 5, trombospondina tipo I dominio 6)] y anti-[*Homo sapiens* ALB (albúmina, sero albúmina humana, SAH)], anticuerpo monoclonal *Lama glama* y humanizado, biespecífico bivalente;
sc VH-VH' (1-275) [*Lama glama* VH anti-ADAMTSL5 (*Lama glama* IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01 (100%)/*Homo sapiens* IGHV3-23*04 (80.2%) -(IGHD) -IGHJ1*01 (100%) [8.8.17] (1-124)) -linker 35-mer (GGGGS)7 (125-159)-VH humanizado anti-ALB (*Homo sapiens* IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8] (160-275),
producido en la levadura Pichia pastoris, no glicosilado

scVH-VH' chain / Chaîne scVH-VH' / Cadena scVH-VH'

```
DVQLVESGGG VVQPGGSLRL SCAASGRTVS SYAMGWFRQA PGKEREFVAG  50
ISRSAERTYY VDSLKGRFTI SRDNSKNTVY LQMNSLRPED TALYYCAADL 100
DPNRIFSREE YAYWGQGTLV TVSSGGGGSG GGGSGGGGSG GGGSGGGGSG 150
GGGSGGGGSE VQLVESGGGV VQPGNSLRLS CAASGFTFSS FGMSWVRQAP 200
GKGLEWVSSI SGSGSDTLYA DSVKGRFTIS RDNAKTTLYL QMNSLRPEDT 250
ALYYCTIGGS LSRSSQGTLV TVSSA                            275
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-single chain (C23-C104) 22-96 181-255

No N-glycosylation sites / pas de sites de N-glycosylation / ningún positión de N-glicosilación


itacnosertibum

itacnosertib — N^4-([2,2'-bipyridin]-3-yl)-N^2-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]pyrimidine-2,4-diamine

itacnosertib — N^4-([2,2'-bipyridin]-3-yl)-N^2-[3-méthoxy-4-(4-méthylpipérazin-1-yl)phényl]pyrimidine-2,4-diamine

itacnosertib — N^4-([2,2'-bipiridin]-3-il)-N^2-[4-(4-metilpiperazin-1-il)-3-metoxifenil]pirimidina-2,4-diamina

$C_{26}H_{28}N_8O$



itepekimabum #

itepekimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* IL33 (interleukin 33, interleukin-1 family member 11, IL1F11, nuclear factor for high endothelial venules, NF-HEV)], monoclonal antibody;
gamma4 heavy chain (1-449) [VH (*Homo sapiens* IGHV3-23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), hinge 1-12 S10>P (230)(221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (96.8%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

itépékimab — immunoglobuline G4-kappa, anti-[*Homo sapiens* IL33 (interleukine 33, membre 11 de la famille 1 d'interleukines, IL1F11, facteur nucléaire des veinules à haut endothélium, NF-HEV)], anticorps monoclonal;
chaîne lourde gamma4 (1-449)) [VH (*Homo sapiens* IGHV3-23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), charnière 1-12 S10>P (230)(221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (96.8%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (228-228":231-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

itepekimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* IL33 (interleukina 33, miembro 11 de la familia 1 de interleukinas, IL1F11, factor nuclear de las vénulas del endotelio alto, NF-HEV)], anticuerpo monoclonal; cadena pesada gamma4 (1-449)) [VH (*Homo sapiens* IGHV3-23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), bisagra 1-12 S10>P (230)(221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (96.8%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (228-228":231-231")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGN LEQPGGSLRL SCTASGFTFS RSAMNWVRRA PGKGLEWVSG  50
ISGSGGRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLSAED TAAYYCAKDS 100
YTTSWYGGMD VWGHGTTVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS VSASVGDRVT ITCRASQGIF SWLAWYQQKP GKAPKLLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFAIYYCQQ ANSVPITFGQ 100
GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	149-205	263-323	369-427
	22"-96"	149"-205"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	136-214'	136"-214'"		
Inter-H-H (h 8, h 11)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
449, 449"

izaflortaucipirum (^{18}F)

izaflortaucipir (^{18}F)

2-(2-(^{18}F)fluoropyridin-4-yl)-9*H*-pyrrolo[2,3-*b*:4,5-*c*']dipyridine


izaflortaucipir (^{18}F)

2-(2-(^{18}F)fluoropyridin-4-yl)-9*H*-pyrrolo[2,3-*b*:4,5-*c*']dipyridine

izaflortaucipir (^{18}F)

2-(2-(^{18}F)fluoropiridin-4-il)-9*H*-pirrolo[2,3-*b*:4,5-*c*']dipiridina

$C_{15}H_9{}^{18}FN_4$



izokibepum #	
izokibep	fusion protein composed of 3 binding domains consisting of three-alpha-helix motifs, each derived from the immunoglobulin (Ig)-binding Z-domain of staphylococcal protein A (SpA), engineered for binding to two homodimer subunits of human interleukin 17A (IL17A) with the two identical N- and C-terminal domains (1-58, 116-173) and to the domain II of human serum albumin (HSA) with the central domain (59-110), connected via a G_4S peptide linker (111-115); [IL17A-binding engineered SpA peptide (1-58)]-[HSA-binding engineered SpA peptide (59-110)]-[G_4S linker (111-115)]-[IL17A-binding engineered SpA peptide (116-173] fusion protein; produced in *Escherichia coli*
izokibep	protéine de fusion composée de 3 domaines liants, chacun consistant en un motif à 3 hélices alpha dérivé du domaine Z de la protéine staphylococcique A (SpA) se liant à l'immunoglobuline (Ig), mis au point pour se lier aux deux homodimères des sous-unités de l'interleukine 17A humaine (IL17A) avec les deux domaines N- et C-terminaux identiques (1-58, 116-173), et au domaine II de l'albumine sérique humaine (ASH, HSA) avec le domaine central (59-110), connecté via un peptide liant G_4S (111-115); protéine de fusion [peptide SpA mis au point pour se lier à l'IL17A (1-58)]-[peptide SpA mis au point pour se lier au HSA (59-110)]-[peptide liant G_4S (111-115)]-[peptide SpA mis au point pour se lier à l'IL17A (116-173)]; produite par *Escherichia coli*
izokibep	proteína de fusión compuesta de 3 dominios de unión, cada uno consistente en un motivo con 3 hélices alfa derivado del dominio Z de la proteína estafilocócica A (SpA) que se une a la inmunoglobulina (Ig), diseñado para unirse a los dos homodímeros de las sub-unidades de la interleukina 17A humana (IL17A) con los dos dominios N- y C-terminal idénticos (1-58, 116-173), y con el dominio II de la albúmina sérica humana (ASH, HSA) con el dominio central (59-110), conectado a través de un péptido que se une a G_4S (111-115); proteína de fusión [péptido SpA diseñado para unirse a la IL17A (1-58)]-[péptido SpA diseñado para unirse al HSA (59-110)]-[G_4S linker (111-115)]-[péptido SpA diseñado para unirse a la IL17A (116-173)]; producida por *Escherichia coli*

Sequence / Séquence / Secuencia

```
AEAKYAKEAD DAAVEIASLP NLTWDQWYAF IQKLRDDPSQ SSELLSEAKK   50
LNDSQAPKAS GSLAEAKEAA NAELDSYGVS DFYKRLIDKA KTVEGVEALK  100
DAILAALPGT GGGGSAEAKY AKEADDAAVE IASLPNLTWD QWYAFIQKLR  150
DDPSQSSELL SEAKKLNDSQ APK                               173
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales
None / aucune / ninguna


lazuvapagonum

lazuvapagon — (4*S*)-*N*-[(2*S*)-1-hydroxypropan-2-yl]-methyl-1-[2-methyl-4-(3-methyl-1*H*-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1*H*-1-benzazepine-4-carboxamide

lazuvapagon — (4*S*)-*N*-[(2*S*)-1-hydroxypropan-2-yl]-méthyl-1-[2-méthyl-4-(3-méthyl-1*H*-pyrazol-1-yl)benzoyl]-2,3,4,5-tétrahydro-1*H*-1-benzazépine-4-carboxamide

lazuvapagón — (4*S*)-*N*-[(2*S*)-1-hidroxipropan-2-il]-metil-1-[2-metil-4-(3-metil-1*H*-pirazol-1-il)benzoil]-2,3,4,5-tetrahidro-1*H*-1-benzazepina-4-carboxamida

$C_{27}H_{32}N_4O_3$



lecanemabum #

lecanemab — immunoglobulin G1-kappa, anti-[*Homo sapiens* APP (amyloid beta A4 precursor protein) soluble beta-amyloid protofibril], monoclonal antibody;
gamma1 heavy chain (1-454) [VH (*Homo sapiens* IGHV3-48*01 (89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (*Mus musculus* IGKV1-117*01 (91%) -IGKJ1*02 (90.9%)/*Homo sapiens* IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-219')];
dimer (233-233'':236-236'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

lécanémab — immunoglobuline G1-kappa, anti-[*Homo sapiens* APP (protéine précurseur amyloïde bêta A4) protofibrille bêta amyloïde soluble], anticorps monoclonal;
chaîne lourde gamma1 (1-454) [VH (*Homo sapiens* IGHV3-48*01 (89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-219')-disulfure avec la chaîne légère kappa

(1'-219') [V-KAPPA (*Mus musculus* IGKV1-117*01 (91%) -IGKJ1*02 (90.9%)/*Homo sapiens* IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-219')];
dimère (233-233":236-236")-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

lecanemab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* APP (proteína precusor amiloide beta A4) protofibrilla beta amiloide soluble], anticuerpo monoclonal;
cadena pesada gamma1 (1-454) [VH (*Homo sapiens* IGHV3-48*01 (89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (*Mus musculus* IGKV1-117*01 (91%) -IGKJ1*02 (90.9%)/*Homo sapiens* IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-219')];
dímero (233-233":236-236")-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCSASGFTFS SFGMHWVRQA PGKGLEWVAY  50
ISSGSSTIYY GDTVKGRFTI SRDNAKNSLF LQMSSLRAED TAVYYCAREG 100
GYYYGRSYYT MDYWGQGTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                    454
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTPGAPAS ISCRSSQSIV HSNGNTYLEW YLQKPGQSPK  50
LLIYKVSNRF SGVPDRFSGS GSGTDFTLRI SRVEAEDVGI YYCFQGSHVP 100
PTFGPGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	151-207	268-328	374-432
	22"-96"	151"-207"	268"-328"	374"-432"
Intra-L (C23-C104)	23'-93'	139'-199'		
	23'"-93'"	139'"-199'"		
Inter-H-L (h 5-CL 126)	227-219'	227"-219'"		
Inter-H-H (h 11, h 14)	233-233"	236-236"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2: 454, 454"

lorpucitinibum

lorpucitinib

2-{1-[*trans*-4-(cyanomethyl)cyclohexyl]-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl}-*N*-(2-hydroxy-2-methylpropyl)acetamide


lorpucitinib

2-{1-[*trans*-4-(cyanométhyl)cyclohexyl]-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl}-*N*-(2-hydroxy-2-méthylpropyl)acetamide

lorpucitinib

2-{1-[*trans*-4-(cianometil)ciclohexil]-1,6-dihidroimidazo[4,5-*d*]pirrolo[2,3-*b*]piridin-2-il}-*N*-(2-hidroxi-2-metilpropil)acetamida


$C_{22}H_{28}N_6O_2$



luvadaxistatum

luvadaxistat	4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2*H*)-one
luvadaxistat	4-hydroxy-6-{2-[4-(trifluorométhyl)phényl]éthyl}pyridazin-3(2*H*)-one
luvadaxistat	4-hidroxi-6-{2-[4-(trifluorometil)fenil]etil}piridazin-3(2*H*)-ona

$C_{13}H_{11}F_3N_2O_2$



miptenalimabum #

miptenalimab	immunoglobulin G4-kappa, anti-[*Homo sapiens* LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], monoclonal antibody; gamma4 heavy chain (1-448) [VH (*Homo sapiens* IGHV3-33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), hinge 1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/*Homo sapiens* IGKV1-39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
mipténalimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* LAG3 (activateur 3 des lymhocytes, lymphocyte-activation 3, CD223)], anticorps monoclonal; chaîne lourde gamma4 (1-448) [VH (*Homo sapiens* IGHV3-33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), charnière 1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/*Homo sapiens* IGKV1-39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228":231-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

miptenalimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* LAG3 (activador 3 de los linfocitos, linfocito-activación 3, CD223)], anticuerpo monoclonal;
cadena pesada gamma4 (1-448) [VH (*Homo sapiens* IGHV3-33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122) - *Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), bisagra 1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/*Homo sapiens* IGKV1-39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (228-228":231-231")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVTLVESGGG VVQPGRSLRL SCAFSGFSLS TSDMGVGWIR QAPGKGLEWV  50
AHIWWDDVKR YNPALKSRFT ISRDNSKNTL YLQMNSLRAE DTAVYFCARI 100
EDYGVSYYFD YWGQGTTVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLG   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSF LSASVGDRVS ITCKASQDVS TAVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPD RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSIPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-97	149-205	263-323	369-427
	22"-97"	149"-205"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	136-214'	136"-214'"		
Inter-H-H (h 8, h 11)	228-228"	231-231"		

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1: 1, 1"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

mirdametinibum

mirdametinib

N-[(2*R*)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide


mirdamétinib

N-[(2*R*)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide

mirdametinib

N-[(2*R*)-2,3-dihidroxipropoxi]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide

$C_{16}H_{14}F_3IN_2O_4$



miromavimabum #

miromavimab	immunoglobulin G1-kappa, anti-[rabies virus strain ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-II], *Mus musculus* monoclonal antibody; gamma1 heavy chain *Mus musculus* (1-445) [VH (*Mus musculus* IGHV1S130*01 (93.9%) -(IGHD) -IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Mus musculus* IGHG1*02 (CH1 Q100>E (199) (122-218), hinge 1-13 (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-214')-disulfide with kappa light chain *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Mus musculus* IGKC*01 (100%) (108'-214')]; dimer (225-225":228-228":230-230")-trisdisulfide, produced in mouse myeloma cell line SP2/0-Ag14, glycoform alfa
miromavimab	immunoglobuline G1-kappa, anti-[épitope G-II de l'ectodomaine de la glycoprotéine de la souche ERA (Evelyn-Rockitniki-Abelseth) du virus de la rage], anticorps monoclonal *Mus musculus*; chaîne lourde gamma1 *Mus musculus* (1-445) [VH (*Mus musculus* IGHV1S130*01 (93.9%) -(IGHD) -IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Mus musculus* IGHG1*02 (CH1 Q100>E (199) (122-218), charnière 1-13 (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-214')-disulfure avec la chaîne légère kappa *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Mus musculus* IGKC*01 (100%) (108'-214')]; dimère (225-225":228-228":230-230")-trisdisulfure, produite dans la lignée cellulaire de myélome murin SP2/0-Ag14, glycoforme alfa
miromavimab	inmunoglobulina G1-kappa, anti-[epítopo G-II del ectodominio de la glicoproteína de la cepa ERA (Evelyn-Rockitniki-Abelseth) del virus de la rabia], anticuerpo monoclonal *Mus musculus*; cadena pesada gamma1 *Mus musculus* (1-445) [VH (*Mus musculus* IGHV1S130*01 (93.9%) -(IGHD) -IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Mus musculus* IGHG1*02 (CH1 Q100>E (199) (122-218), bisagra 1-13 (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-214')-disulfuro con la cadena ligera kappa *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Mus musculus* IGKC*01 (100%) (108'-214')]; dímero (225-225":228-228":230-230")-trisdisulfuro, producida en la línea celular de mieloma murino SP2/0-Ag14, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQPGSV LVRPGASVKL SCKTSGYAFT SSWMHWAKQR PGQGLEWIGQ  50
THPNSGYTNY NEKFKGKATL TVDTSSSTAY VDLSSLTSED SAVYYCARES 100
GDGPHWYFDV WGAGTAVTVS SAKTTPPSVY PLAPGSAAQT NSMVTLGCLV 150
KGYFPEPVTV TWNSGSLSSG VHTFPAVLQS DLYTLSSSVT VPSSTWPSET 200
VTCNVAHPAS STKVDKKIVP RDCGCKPCIC TVPEVSSVFI FPPKPKDVLT 250
ITLTPKVTCV VVDISKDDPE VQFSWFVDDV EVHTAQTQPR EEQFNSTFRS 300
VSELPIMHQD WLNGKEFKCR VNSAAFPAPI EKTISKTKGR PKAPQVYTIP 350
PPKEQMAKDK VSLTCMITDF FPEDITVEWQ WNGQPAENYK NTQPIMDTDG 400
SYFVYSKLNV QKSNWEAGNT FTCSVLHEGL HNHHTEKSLS HSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSHKF MSTSVGDRVS ITCKASQDVS TAVAWYQQKP GQSPKLLIYS  50
ASYRYTGVPD RFTGSGSGTD FTFTISSVQA EDLAVYYCQQ HYSSPHTFGG 100
GTKLETKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI 150
DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT 200
STSPIVKSFN RNEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-203	259-319	365-423
	22"-96"	148"-203"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	223-214'	223"-214'"		
Inter-H-H (h 7, h 10, h 12)	225-225"	228-228"	230-230"	

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"
Fucosylated complex biantennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

modakafuspum alfa #

modakafusp alfa — immunoglobulin G4-kappa, anti-[human ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (EC:3.2.2.6) (ADPRC 1/cADRp hydrolase 1, cell surface antigen CD38)], humanized monoclonal antibody, fused at each C-terminus of the heavy chains (1-447, 1"-447") to attenuated human interferon α-2b (IFNα2b) variant (K^{23}>R^{470}, T^{106}>A^{553}, A^{145}>D^{592}) (448-612, 448"-612"); gamma4 heavy chain humanized fused to IFNα2b (1-612) [VH (*Homo sapiens* IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), hinge 1-12 S^{10}>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(121-447), fused to IFNα2b K^{23}>R (470), T^{106}>A (553), A^{145}>D (592) (448-612)],(134-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V^{101} (191) (108'-214')]; dimer (226-226":229-229")-bisdisulfide;
produced in Chinese hamster ovary (CHO) K1SV cells, glycoform alfa

modakafusp alfa — immunoglobuline G4-kappa, anti-[ADP-ribosyl cyclase/ ADP cyclique - ribose hydrolase 1 humaine (EC:3.2.2.6) (ADPRC 1/cADRp hydrolase 1, antigène de surface cellulaire CD38)], anticorps monoclonal humain fusionné à chaque partie C-terminale des chaînes lourdes (1-447, 1"-447") à un variant (K^{23}>R^{470}, T^{106}>A^{553}, A^{145}>D^{592}) de l'interféron α-2b humain (IFNα2b) atténué, (448-612, 448"-612");
chaîne lourde gamma4 humanisée fusionnée à IFNα2b (1-612) [VH (*Homo sapiens* IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), charnière 1-12 S^{10}>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(121-447), fusionné à IFNα2b K^{23}>R (470), T^{106}>A (553), A^{145}>D (592) (448-612)],(134-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V^{101} (191) (108'-214')]; dimère (226-226":229-229")-bisdisulfure ;
produit dans des cellules ovariennes de hamster chinois (CHO) K1SV, glycoforme alfa

modakafusp alfa

inmunoglobulina G4-kappa, anti-[ADP-ribosil ciclasa/ ADP cíclica -ribosa hidrolasa 1 humana (EC:3.2.2.6) (ADPRC 1/cADRp hidrolasa 1, antígeno de superficie celular CD38)], anticuerpo monoclonal humano fusionado a cada parte C-terminal de las cadenas pesadas (1-447, 1"-447") a una variante (K^{23}>R^{470}, T^{106}>A^{553}, A^{145}>D^{592}) del interferón α-2b humano (IFNα2b) atenuado, (448-612, 448"-612"); cadena pesada gamma4 humanizada fusionada al IFNα2b (1-612) [VH (*Homo sapiens* IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), bisagra 1-12 S^{10}>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(121-447), fusionado con IFNα2b K^{23}>R (470), T^{106}>A (553), A^{145}>D (592) (448-612)],(134-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V^{101} (191) (108'-214')]; dímero (226-226":229-229")-bisdisulfuro ; producido en las células ováricas de hamster chino (CHO) K1SV, glicoforma alfa

Sequence / Séquence / Secuencia

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD38 γ4-IFNα2b)

```
EVQLVQSGAE VKKPGATVKI SCKVSGYTFT DSVMNWVQQA PGKGLEWMGW   50
IDPEYGRTDV AEKFQGRVTI TADTSTDTAY MELSSLRSED TAVYYCARTK  100
YNSGYGFPYW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK  150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT  200
YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT  250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY  300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT  350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS  400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGKCDL  450
PQTHSLGSRR TLMLLAQMRR ISLFSCLKDR HDFGFPQEEF GNQFQKAETI  500
PVLHEMIQQI FNLFSTKDSS AAWDETLLDK FYTELYQQLN DLEACVIQGV  550
GVAETPLMKE DSILAVRKYF QRITLYLKEK KYSPCAWEVV RDEIMRSFSL  600
STNLQESLRS KE                                           612
```

Light chain / chaîne légère / cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQNVD SDVDWYQQKP GKAPKLLIYK   50
ASNDYTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCMQ SNTHPRTFGG  100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  200
LSSPVTKSFN RGEC                                         214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	147-203	261-321	367-425
	22"-96"	147"-203"	261"-321"	367"-425"
Intra-IFN	448-545	476-585	448"-545"	476"-585"
Intra-L	23'-88'	134'-194'	23'"-88'"	134'"-194'"
Inter-H-L	134-214'	134"-214'"		
Inter-H-H	226-226"	229-229"		


Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

H CH2 N84.4: N297, N297"

Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

murizatoclaxum
murizatoclax

(1^{3}*S*,3^{1}*R*,3^{2}*R*,4*R*,5*E*,8*S*,9*R*)-6'-chloro-4-methoxy-8,9-dimethyl-4-{[(9a*R*)-octahydro-2*H*-pyrido[1,2-*a*]pyrazin-2-yl]methyl}-3',4'-dihydro-1^{2}*H*,1^{4}*H*,2'*H*-spiro[10λ^{6}-thia-11-aza-1(5,7)-[1,5]benzoxazepina-3(1,2)-cyclobutanacyclododecaphan-5-ene-1^{3},1'-naphthalene]-10,10,12-trione

murizatoclax	(1^{3}*S*,3^{1}*R*,3^{2}*R*,4*R*,5*E*,8*S*,9*R*)-6'-chloro-4-méthoxy-8,9-diméthyl-4-{[(9a*R*)-octahydro-2*H*-pyrido[1,2-*a*]pyrazin-2-yl]méthyl}-3',4'-dihydro-1^{2}*H*,1^{4}*H*,2'*H*-spiro[10λ^{6}-thia-11-aza-1(5,7)-[1,5]benzoxazépina-3(1,2)-cyclobutanacyclododécaphan-5-ène-1^{3},1'-naphtalène]-10,10,12-trione
murizatoclax	(1^{3}*S*,3^{1}*R*,3^{2}*R*,4*R*,5*E*,8*S*,9*R*)-6'-cloro-4-metoxi-8,9-dimetil-4-{[(9a*R*)-octahidro-2*H*-pirido[1,2-*a*]pirazin-2-il]metil}-3',4'-dihidro-1^{2}*H*,1^{4}*H*,2'*H*-spiro[10λ^{6}-thia-11-aza-1(5,7)-[1,5]benzoxazepina-3(1,2)-ciclobutanaciclododecafan-5-eno-1^{3},1'-naftaleno]-10,10,12-triona $C_{42}H_{57}ClN_4O_5S$ 
nadunolimabum # nadunolimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* IL1RAP (interleukin-1 receptor accessory protein)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-446) [VH (*Homo sapiens* IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), hinge (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS K2>del (446)) (118-446)], (220-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226":229-229")-bisdisulfide
nadunolimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* IL1RAP (interleukin-1 receptor accessory protein)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-446) [VH (*Homo sapiens* IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), hinge (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS K2>del (446)) (118-446)], (220-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226":229-229")-bisdisulfide

nadunolimab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL1RAP (interleukin-1 receptor accessory protein)], humanized monoclonal antibody;
gamma1 heavy chain humanized (1-446) [VH (*Homo sapiens* IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), hinge (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS K2>del (446)) (118-446)], (220-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226":229-229")-bisdisulfide

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYAFT SSWMNWVRQA PGQGLEWMGR  50
IYPGDGNTHY AQKFQGRVTL TADKSTSTAY MELSSLRSED TAVYYCGEGY 100
LDPMDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCQASQGIN NYLNWYQQKP GKAPKLLIHY  50
TSGLHAGVPS RFSGSGSGTD YTLTISSLEP EDVATYYCQQ YSILPWTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfur
Intra-H (C23-C104) 22-96 144-200 261-321 367-425
22"-96" 144"-200" 261"-321" 367"-425"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 220-214' 220"-214'"
Inter-H-H (h 11, h 14) 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297'
Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennai complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados.

nesolicaftorum

nesolicaftor

N-(*trans*-3-{5-[(1*R*)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl}cyclobutyl)-3-phenyl-1,2-oxazole-5-carboxamide


nésolicaftor

N-(*trans*-3-{5-[(1*R*)-1-hydroxyéthyl]-1,3,4-oxadiazol-2-yl}cyclobutyl)-3-phenyl-1,2-oxazole-5-carboxamide

nesolicaftor

3-fenil-*N*-(*trans*-3-{5-[(1*R*)-1-hidroxietil]-1,3,4-oxadiazol-2-il}ciclobutil)-1,2-oxazolo-5-carboxamida

$C_{18}H_{18}N_4O_4$



nipocalimabum #

nipocalimab	immunoglobulin G1-lambda, anti-[*Homo sapiens* FCGRT (Fc fragment of IgG receptor and transporter, neonatal Fc receptor, FcRn, transmembrane alpha chain of the neonatal receptor)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-445) [VH (*Homo sapiens* IGHV3-23*01 (90.8%) -(IGHD) - IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97-105) (1-116) -*Homo sapiens* IGHG1*03 G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1 R120>K (213) (117-214), hinge 1-15 (215-229), CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-215')-disulfide with lambda light chain *Homo sapiens* (1'-216') [V-LAMBDA (*Homo sapiens* IGLV2-23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26-34.52-54.91-100) (1'-110') -*Homo sapiens* IGLC3*03 (100%) (111'-216')]; dimer (225-225":228-228")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
nipocalimab	immunoglobuline G1-lambda, anti-[*Homo sapiens* FCGRT (transporteur et récepteur du fragment Fc des IgG, récepteur Fc néonatal, FcRn, chaîne alpha transmembranaire du récepteur néonatal)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 *Homo sapiens* (1-445) [VH (*Homo sapiens* IGHV3-23*01 (90.8%) -(IGHD) - IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97-105) (1-116) -*Homo sapiens* IGHG1*03 G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1 R120>K (213) (117-214), charnière 1-15 (215-229), CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-215')-disulfure avec la chaîne légère lambda *Homo sapiens* (1'-216') [V-LAMBDA (*Homo sapiens* IGLV2-23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26-34.52-54.91-100) (1'-110') -*Homo sapiens* IGLC3*03 (100%) (111'-216')]; dimère (225-225":228-228")-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
nipocalimab	inmunoglobulina G1-lambda, anti-[*Homo sapiens* FCGRT (transportador y receptor del fragmento Fc de las IgG, receptor Fc neonatal, FcRn, cadena alfa transmembranaria del receptor neonatal)], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma1 *Homo sapiens* (1-445) [VH (*Homo sapiens* IGHV3-23*01 (90.8%) -(IGHD) - IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97-105) (1-116) -*Homo sapiens* IGHG1*03 G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1 R120>K (213) (117-214), bisagra 1-15 (215-229), CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-215')-disulfuro con la cadena ligera lambda *Homo sapiens* (1'-216') [V-LAMBDA (*Homo sapiens* IGLV2-23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26-34.52-54.91-100) (1'-110') -*Homo sapiens* IGLC3*03 (100%) (111'-216')]; dímero (225-225":228-228")-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS TYAMGWVRQA PGKGLEWVSS  50
IGASGSQTRY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARLA 100
IGDSYWGQGT MVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYASTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG      445
```

Light chain / Chaîne légère / Cadena ligera

```
QSALTQPASV SGSPGQSITI SCTGTGSDVG SYNLVSWYQQ HPGKAPKLMI  50
YGDSERPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYAGSGIYV 100
FGTGTKVTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHKSYSCQVT 200
HEGSTVEKTV APTECS                                      216
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	143-199	260-320	366-424
	22"-96"	143"-199"	260"-320"	366"-424"
Intra-L (C23-C104)	22'-90'	138'-197'		
	22'"-90'"	138'"-197'"		
Inter-H-L (h 5-CL 126)	219-215'	219"-215'"		
Inter-H-H (h 11, h 14)	225-225"	228-228"		

No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación

H CH2 N84.4>A:
296, 296"

olverembatinibum

olverembatinib

4-methyl-*N*-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[(1*H*-pyrazolo[3,4-*b*]pyridin-5-yl)ethynyl]benzamide


olvérembatinib

4-méthyl-*N*-{4-[(4-méthylpipérazin-1-yl)méthyl]-3-(trifluorométhyl)phényl}-3-[(1*H*-pyrazolo[3,4-*b*]pyridin-5-yl)éthynyl]benzamide

olverembatinib

4-metil-*N*-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}-3-[(1*H*-pirazolo[3,4-*b*]piridin-5-il)etinil]benzamide

$C_{29}H_{27}F_3N_6O$



olvimulogenum nanivacirepvecum #

olvimulogene nanivacirepvec

A recombinant replication-competent oncolytic vaccinia virus (strain LIVP) comprising the genes encoding a Renilla luciferase - green fluorescent protein fusion protein (ruc-gfp) and enzymes beta-galactosidase (lacZ) and beta-glucuronidase (gusA), inserted into the F14.5L, J2R (thymidine kinase) and A56R (hemagglutinin) loci, respectively. Expression of the three proteins is driven by a synthetic early/late promoter (pSEL), a vaccinia virus strain Western Reserve early/late p7.5 promoter and a vaccinia virus strain Western Reserve late p11 promoter, respectively. A human transferrin receptor gene has also been inserted in the J2R locus but is not expressed.

olvimulogène nanivacirépvec	virus de la vaccine recombinant répliquant oncolytique (souche LIVP) contenant les gènes codant pour une protéine de fusion luciférase de Renilla - protéine fluorescente verte (ruc-gfp) et des enzymes galactosidase bêta (lacZ) et glucuronidase bêta (gusA), insérés dans les loci F14.5L, J2R (thymidine kinase) and A56R (hémagglutinine), respectivement. L'expression des trois protéines est sous le contrôle d'un promoteur synthétique précoce/tardif (pSEL), d'un promoteur p7.5 précoce/tardif du virus de la vaccine souche Western Reserve et d'un promoteur p11 tardif du virus de la vaccine souche Western Reserve, respectivement. Un gène du récepteur de transférine humain a aussi été inséré dans le locus J2R mais n'est pas exprimé.
olvimulogén nanivacirepvec	Un virus vaccinia recombinante (cepa LIVP) competente para replicación, oncolítico, que contiene los genes que codifican para una proteína de fusión de la luciferasa de Renilla y la proteína fluorescente verde (ruc-gfp) y para las enzimas beta-galactosidasa (LacZ) y beta-glucuronidasa (gusA), insertados en los loci F14.5L, J2R (timidina quinasea) y A56R (hemaglutinina), respectivamente. La expresión de las tres proteínas está dirigida por un promotor temprano/tardío sintético (pSEL), un promotor p7.5 precoz/tardío de la cepa Western Reserve del virus vaccinia y un promotor p11 tardío de la cepa Western Reserve del virus vaccinia, respectivamente. Se ha insertado también un gen del receptor de transferrina humano en el locus J2R pero éste no se expresa.

omfiloctocogum alfa #

omfiloctocog alfa	human coagulation factor VIII (FVIII, antihemophilic factor, AHF, procoagulant component) with deleted B-domain (746-1639)-sequence: single-chain recombinant FVIII composed of domains A1-a1-A2-a2 (1-740), the B-domain N- and C-terminal fragments (741-745) and 1640-1648 (746-754) and domains a3-A3-C1-C2 1649-2332 (755-1438), produced in Chinese hamster ovary (CHO) cells, glycoform alfa
omfiloctocog alfa	facteur de coagulation VIII humain (FVIII, facteur antihémophilique, AHF, composant procoagulant) dont le domaine B a été supprimé (746-1639): chaîne unique du FVIII humain recombinant composé des domaines A1-a1-A2-a2 (1-740), des fragments N- and C-terminaux du domaine B (741-745) et 1640-1648 (746-754) et des domaines a3-A3-C1-C2 1649-2332 (755-1438), produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
omfiloctocog alfa	factor de coagulación VIII humano (FVIII, factor antihemofílico, AHF, componente procoagulante) con el dominio B que ha sido suprimido (746-1639):

cadena única del FVIII humano recombinante compuesto de los dominios A1-a1-A2-a2 (1-740), de los fragmentos N- y C-terminal del dominio B (741-745) y 1640-1648 (746-754) y de los dominios a3-A3-C1-C2 1649-2332 (755-1438), producido por las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL    50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA   100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD   150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA   200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR   250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL   300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL   350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL   400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG   450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD   500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP   550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG   600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS   650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR   700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNPPVLK   750
RHQREITRTT LQSDQEEIDY DDTISVEMKK EDFDIYDEDE NQSPRSFQKK   800
TRHYFIAAVE RLWDYGMSSS PHVLRNRAQS GSVPQFKKVV FQEFTDGSFT   850
QPLYRGELNE HLGLLGPYIR AEVEDNIMVT FRNQASRPYS FYSSLISYEE   900
DQRQGAEPRK NFVKPNETKT YFWKVQHHMA PTKDEFDCKA WAYFSDVDLE   950
KDVHSGLIGP LLVCHTNTLN PAHGRQVTVQ EFALFFTIFD ETKSWYFTEN  1000
MERNCRAPCN IQMEDPTFKE NYRFHAINGY IMDTLPGLVM AQDQRIRWYL  1050
LSMGSNENIH SIHFSGHVFT VRKKEEYKMA LYNLYPGVFE TVEMLPSKAG  1100
IWRVECLIGE HLHAGMSTLF LVYSNKCQTP LGMASGHIRD FQITASGQYG  1150
QWAPKLARLH YSGSINAWST KEPFSWIKVD LLAPMIIHGI KTQGARQKFS  1200
SLYISQFIIM YSLDGKKWQT YRGNSTGTLM VFFGNVDSSG IKHNIFNPPI  1250
IARYIRLHPT HYSIRSTLRM ELMGCDLNSC SMPLGMESKA ISDAQITASS  1300
YFTNMFATWS PSKARLHLQG RSNAWRPQVN NPKEWLQVDF QKTMKVTGVT  1350
TQGVKSLLTS MYVKEFLISS SQDGHQWTLF FQNGKVKVFQ GNQDSFTPVV  1400
NSLDPPLLTR YLRIHPQSWV HQIALRMEVL GCEAQDLY               1438
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179, 248-329, 528-554, 630-711, 938-964, 1005-1009, 1127-1275, 1280-1432
(Cys-SH: 310, 692, 1106)

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N41, N239, N916, N1224
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

Tyr-sulfation sites / Sites de Tyr-sulfation / Posiciones de Tyr-sulfación
346, 718, 719, 723, 770, 786


onatasertibum

onatasertib — 7-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-(*trans*-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-*b*]pyrazin-2(1*H*)-one

onatasertib — 7-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-(*trans*-4-méthoxycyclohexyl)-3,4-dihydropyrazino[2,3-*b*]pyrazin-2(1*H*)-one

onatasertib — 7-[6-(2-hidroxipropan-2-il)piridin-3-il]-1-(*trans*-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-*b*]pirazin-2(1*H*)-ona

$C_{21}H_{27}N_5O_3$



ongericimabum #

ongericimab	immunoglobulin G4-kappa, anti-[*Homo sapiens* PCSK9 (proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9)], humanized monoclonal antibody; gamma4 heavy chain (1-438) [VH (*Homo sapiens* IGHV4-59*01 (79.2%) -(IGHD) -IGHJ1*01 (100%)) CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) - *Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (112-209), hinge 1-12 S10>P (219) (210-221), CH2 (222-331), CH3 (332-436), CHS (437-438)) (112-438)], (125-213')-disulfide with kappa light chain (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.1%) - IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (217-217'':220-220'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
ongéricimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* PCSK9 (proprotéine convertase subtilisine/kexine type 9, convertase 1 régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine convertase 9, PC9)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-438) [VH (*Homo sapiens* IGHV4-59*01 (79.2%) -(IGHD) - IGHJ1*01 (100%)) CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) - *Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (112-209), charnière 1-12 S10>P (219) (210-221), CH2 (222-331), CH3 (332-436), CHS (437-438)) (112-438)], (125-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.1%) -IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (217-217'':220-220'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
ongericimab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* PCSK9 (proproteína convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la apoptosa neuronal, NARC1, NARC-1, proproteína convertasa 9, PC9)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-438) [VH (*Homo sapiens* IGHV4-59*01 (79.2%) -(IGHD) - IGHJ1*01 (100%)) CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) - *Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (112-209), bisagra 1-12 S10>P (219) (210-221), CH2 (222-331), CH3 (332-436), CHS (437-438)) (112-438)], (125-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.1%) -IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (217-217'':220-220'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSQTLSL TCTVSGFSIS SYGIHWIRQS PGKGLEWIGV  50
IWRGGITDYN APFMSRVTIS KDNSKNQVSF KLSSVTAADT AVYYCANHRD 100
WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV 150
SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK TYTCNVDHKP 200
SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD TLMISRTPEV 250
TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST YRVVSVLTVL 300
HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT 350
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR 400
LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK              438
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCQASQDIN KYIDWYQHKP GKAPKLLIHY  50
ASTLQPGVPS RFSGSGSGRD YTFTISSLQP EDIATYYCLQ YDDLWTFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                        213
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	138-194	252-312	358-416
	22''-95''	138''-194''	252''-312''	358''-416''
Intra-L (C23-C104)	23'-88'	133'-193'		
	23'''-88'''	133'''-193'''		
Inter-H-L (CH1 10-CL 126)	125-213'	125''-213'''		
Inter-H-H (h 8, h 11)	217-217''	220-220''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

288, 288''

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

ontorpaceptum #

ontorpacept	human signal-regulatory protein alpha (SIRPα, tyrosine-protein phosphatase non-receptor type substrate 1, inhibitory receptor SHPS-1), (L^{14}>S, T^{20}>S, T^{22}>I, R^{24}>H, A^{27}>V, G^{45}>A, D^{65}>E, L^{66}>S, N^{70}>E, R^{77}>S, G^{79}>S, D^{101}>del, V^{102}>T^{101})-variant, N-terminal (1-118)-fragment [binding domain for CD47 (inhibitor of phagocytosis by macrophages)], fused to a human immunoglobulin G1 C-terminal Fc fragment (119-345), dimer (124-124':127-127')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
ontorpacept	protéine régulatoire de signal alpha, humaine (SIRPα, substrat 1 de type non-récepteur de la tyrosine-protéine phosphatase, récepteur inhibitoire SHPS-1), (L^{14}>S, T^{20}>S, T^{22}>I, R^{24}>H, A^{27}>V, G^{45}>A, D^{65}>E, L^{66}>S, N^{70}>E, R^{77}>S, G^{79}>S, D^{101}>del, V^{102}>T^{101})-variant, fragment N-terminal (1-118) [domaine se liant au CD47 (inhibiteur de la phagocytose par les macrophages)], fusionnée au fragment Fc C-terminal de l'immunoglobuline G1 (119-345), dimère (124-124':127-127')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
ontorpacept	proteína reguladora de señal alfa, humana (SIRPα, sustrato 1 de tipo no-receptor de la tirosina-proteína fosfatasa, receptor inhibidor SHPS-1), (L^{14}>S, T^{20}>S, T^{22}>I, R^{24}>H, A^{27}>V, G^{45}>A, D^{65}>E, L^{66}>S, N^{70}>E, R^{77}>S, G^{79}>S, D^{101}>del, V^{102}>T^{101})-variante, fragmento N-terminal (1-118) [dominio unido al CD47 (inhibidor de la fagocitosis por los macrófagos)], fusionado con el fragmento Fc C-terminal de la inmunoglobulina G1 (119-345), dímero (124-124':127-127')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
EEELQVIQPD KSVSVAAGES AILHCTVTSL IPVGPIQWFR GAGPARELIY   50
NQKEGHFPRV TTVSESTKRE NMDFSISISN ITPADAGTYY CVKFRKGSPD  100
TEFKSGAGTE LSVRAKPSDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM  150
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV  200
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP  250
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG  300
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK       345
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

intra-chain	25-91	159-219	265-323
	25'-91'	159'-219'	265'-323'
inter-chain:	124-124'	127-127'	

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N80, N195, N80', N195'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal
H CHS K2: 345, 345'

opucolimabum #

opucolimab	immunoglobulin G1-lambda, anti-[*Homo sapiens* CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)], monoclonal antibody; gamma1 heavy chain (1-453) [VH (*Homo sapiens* IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-221), hinge 1-15 (222-236), CH2 N84.4>A (303) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with lambda light chain humanized (1'-214') [V-LAMBDA (*Homo sapiens* IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'-109') -*Homo sapiens* IGLC3*03 (98.1%) K119>R (207), P123>L (211) (110'-214')]; dimer (232-232":235-235")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells
opucolimab	immunoglobuline G1-lambda, anti-[*Homo sapiens* CD274 (ligand 1 de mort programmée, PDL1, PD-L1, homologue 1 de B7, B7H1)], anticorps monoclonal; chaîne lourde gamma1 (1-453) [VH (*Homo sapiens* IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-221), charnière 1-15 (222-236), CH2 N84.4>A (303) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure avec la chaîne légère (1'-214') [V-LAMBDA (*Homo sapiens* IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'-109') -*Homo sapiens* IGLC3*03 (98.1%) K119>R (207), P123>L (211) (110'-214')]; dimère (232-232":235-235")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO)
opucolimab	inmunoglobulina G1-lambda, anti-[*Homo sapiens* CD274 (ligando 1 de muerte programada, PDL1, PD-L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal;

cadena pesada gamma1 (1-453) [VH (*Homo sapiens* IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-221), bisagra 1-15 (222-236), CH2 N84.4>A (303) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera lambda (1'-214') [V-LAMBDA (*Homo sapiens* IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'-109') -*Homo sapiens* IGLC3*03 (98.1%) K119>R (207), P123>L (211) (110'-214')]; dímero (232-232":235-235")-bisdisulfuro, producido por células ováricas de hamster chino (CHO)

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGGG LVKPGGSLRL SCAASGFTFS SYTMNWVRQA PGKGLEWVSS  50
ISSGSDYLYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARNE 100
LRWYPQAGAF DRWGQGTMVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYASTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
QSVVTQPPSM SAAPGQRVTI SCSGSSSYIE SSYVGWYQQL PGTAPRLLIY  50
DDDMRPSGIP DRFSGSKSGT SATLAITGLQ TGDEADYYCE IWRSGLGGVF 100
GGGTKLTVLS QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HKSYSCQVTH 200
EGSTVERTVA LTEC                                         214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	150-206	267-327	373-431
	22"-96"	150"-206"	267"-327"	373"-431"
Intra-L (C23-C104)	22'-89'	137'-196'		
	22'"-89'"	137'"-196'"		
Inter-H-L (h 5-CL 126)	226-214'	226"-214'"		
Inter-H-H (h 11, h 14)	232-232"	235-235"		

No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación:
H CH2 N84.4>A:
303, 303"

C-terminal lysine clipping:
H CHS K2:
453, 453"


orelabrutinibum

orelabrutinib — 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-4-yl]pyridine-3-carboxamide

orélabrutinib — 2-(4-phénoxyphényl)-6-[1-(prop-2-énoyl)pipéridin-4-yl]pyridine-3-carboxamide

orelabrutinib — 2-(4-fenoxifenil)-6-[1-(prop-2-enoil)piperidin-4-il]piridina-3-carboxamida

$C_{26}H_{25}N_3O_3$



orvacabtagenum autoleucelum #


orvacabtagene autoleucel	autologous CD4+ and CD8+ T lymphocytes obtained from peripheral blood mononuclear cells (PBMC), transduced *ex vivo* with a replication-incompetent, self-inactivating (SIN) lentiviral vector, encoding a chimeric antigen receptor (CAR) consisting of the human B cell maturation antigen (BCMA)-specific scFv, an IgG4-CH2-CH3 hinge region, CD28 transmembrane domain, CD137 (4-1BB) co-stimulatory domain and CD3 zeta signalling domain, under the control of a hybrid Elongation Factor 1 alpha (EF1α) / Human T cell Leukemia Virus (HTLV) R element promoter. The vector also encodes a truncated human epidermal growth factor receptor (EGFRt) that is expressed separately from the CAR on the cell surface.
orvacabtagène autoleucel	lymphocytes T autologues CD4+ and CD8+ obtenus de cellules mononuclées du sang périphérique (PBMC), transduits *ex vivo* avec un vecteur lentiviral non-répliquant, auto-inactivant (SIN) codant pour un récepteur d'antigène chimérique (CAR) ciblant l'antigène spécifique du scFv de maturation des lymphocytes B (BCMA) humain, une région charnière IgG4-CH2-CH3, un domaine transmembranaire du CD28, un domaine co-stimulateur du CD137 (4-1BB), et un domaine de signalisation CD3 zêta, sous le contrôle d'un promoteur hybride du facteur d'élongation 1-alpha humain (EF1α) / élément R du virus du lymphome humain à cellules T (HTLV). Le vecteur exprime un récepteur du facteur de croissance des cellules épidermiques humain tronqué (EGFRt) qui est exprimé séparément du CAR à la surface de la cellule.
orvacabtagén autoleucel	linfocitos T CD4+ y CD8+ autólogos obtenidos de células mononucleares de sangre periférica, transducidos con un vector lentiviral auto inactivante e incompetente para replicación, que codifica un receptor para antígenos quimérico (CAR) consistente en un ssFv específico del antígeno de maduración de linfocitos B humano (BCMA), una región bisagra IgG4-CH2-CH3, un dominio transmembrana de CD28, un domino coestimulador de CD137 (4-1BB) y un dominio de señalización de CD3 zeta, bajo el control de un promotor híbrido del Factor de Elongación 1 alfa (EF1a) / elemento R del virus de la leucemia de células T (HTLV) humana. El vector también codifica para una forma truncada del receptor del factor de crecimiento epidérmico (EGFRt) humano que se expresa separado del CAR en la superficie celular.

osoresnontrinum

osoresnontrine	1-(oxan-4-yl)-6-[(pyridin-2-yl)methyl]-1,5-dihydro-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-one
osoresnontrine	1-(oxan-4-yl)-6-[(pyridin-2-yl)méthyl]-1,5-dihydro-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-one
osoresnontrina	1-(oxan-4-il)-6-[(piridin-2-il)metil]-1,5-dihidro-4*H*-pirazolo[3,4-*d*]pirimidin-4-ona

751
エーザイ株式会社

$C_{16}H_{17}N_5O_2$



pelacarsenum

pelacarsen

all-P-ambo-5'-*O*-(28-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy]methyl}-1-hydroxy-1,10,14,21-tetraoxo-2,18-dioxa-9,15,22-triaza-1λ^5-phosphaoctacosan-1-yl)-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)guanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)guanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidine


pélacarsen

tout-P-ambo-5'-*O*-(28-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy]méthyl}-1-hydroxy-1,10,14,21-tétraoxo-2,18-dioxa-9,15,22-triaza-1λ^5-phosphaoctacosan-1-yl)-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)guanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyluridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyluridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)guanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidine

pelacarsén

todo-P-ambo-5'-*O*-(28-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis{[3-({6-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]hexil}amino)-3-oxopropoxi]metil}-1-hidroxi-1,10,14,21-tetraoxo-2,18-dioxa-9,15,22-triaza-1λ^5-fosfaoctacosan-1-il)-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)guanilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metiluridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metiluridilil-(3'→5')-2'-*O*-(2-metoxietil)guanilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidina

$C_{296}H_{439}N_{71}O_{163}P_{20}S_{13}$



pelcitoclaxum

pelcitoclax

(3-{[(10*R*)-1^4-chloro-3^5-fluoro-2^4-(methanesulfonyl)-2^5-methyl-7,7-dioxo-10-[(phenylsulfanyl)methyl]-2^1-(propan-2-yl)-8^3-(trifluoromethanesulfonyl)-2^1*H*-7λ^6-thia-6,9-diaza-4(1,4)-piperazina-13(1)-piperidina-2(2,3)-pyrrola-1(1),3(1,3),5,8(1,4)-tetrabenzenatridecaphane-13^4-carbonyl]oxy}propyl)phosphonic acid


pelcitoclax

acide (3-{[(10*R*)-1^4-chloro-3^5-fluoro-2^4-(méthanesulfonyl)-2^5-méthyl-7,7-dioxo-10-[(phénylsulfanyl)méthyl]-2^1-(propan-2-yl)-8^3-(trifluorométhanesulfonyl)-2^1*H*-7λ^6-thia-6,9-diaza-4(1,4)-pipérazina-13(1)-pipéridina-2(2,3)-pyrrola-1(1),3(1,3),5,8(1,4)-tétrabenzenatridécaphane-13^4-carbonyl]oxy}propyl)phosphonique

pelcitoclax

ácido (3-{[(10*R*)-1^4-cloro-10-[(fenilsulfanil)metil]-3^5-fluoro-2^4-(metanosulfonil)-2^5-metil-7,7-dioxo-2^1-(propan-2-il)-8^3-(trifluorometanosulfonil)-2^1*H*-7λ^6-tia-6,9-diaza-4(1,4)-piperazina-13(1)-piperidina-2(2,3)-pirrola-1(1),3(1,3),5,8(1,4)-tetrabencenatridecafano-13^4-carbonil]oxi}propil)fosfónico

$C_{57}H_{66}ClF_4N_6O_{11}PS_4$




pexopiprantum

pexopiprant ({8-chloro-3-[(4-chlorophenyl)methyl]-4-(difluoromethoxy)-2-ethylquinolin-5-yl}oxy)acetic acid

pexopiprant acide ({8-chloro-3-[(4-chlorophényl)méthyl]-4-(difluorométhoxy)-2-éthylquinolin-5-yl}oxy)acétique

pexopiprant ácido ({8-cloro-3-[(4-clorofenil)metil]-4-(difluorometoxi)-2-etilquinolin-5-il}oxi)acético

$C_{21}H_{17}Cl_2F_2NO_4$



pimurutamabum #

pimurutamab immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized monoclonal antibody;
gamma1 heavy chain humanized (1-449) [VH (*Homo sapiens* IGHV3-48*03 (78.6%) -(IGHD) -IGHJ3*01 (85.7%)) [8.7.13] (1-119) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

pimurutamab immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal humanisé;

chaîne lourde gamma1 humanisée (1-449) [VH (*Homo sapiens* IGHV3-48*03 (78.6%) -(IGHD) -IGHJ3*01 (85.7%)) [8.7.13] (1-119) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), charnière 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (228-228":231-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

pimurutamab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 humanizada (1-449) [VH (*Homo sapiens* IGHV3-48*03 (78.6%) -(IGHD) -IGHJ3*01 (85.7%)) [8.7.13] (1-119) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), bisagra 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (228-228":231-231")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFSLT NYGVHWVRQA PGKGLEWLGV  50
IWSGGNTDYG NEFTSRFTIS RDNAKNSLYL QMNSLRAEDT AVYYCARALD 100
YYDYEFAYWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSIG TNIHWYQQKP GQAPRLLIKY  50
ASESISGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ NNNWPTSFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	146-202	263-323	369-427
	22"-95"	146"-202"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	222-214'	222"-214'"		
Inter-H-H (h 11, h 14)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
449, 449"


posenacaftorum

posenacaftor — 8-methyl-2-(3-methyl-1-benzofuran-2-yl)-5-[(1*R*)-1-(oxan-4-yl)ethoxy]quinoline-4-carboxylic acid

posénacaftor — acide 8-méthyl-2-(3-méthyl-1-benzofuran-2-yl)-5-[(1*R*)-1-(oxan-4-yl)éthoxy]quinoléine-4-carboxylique

posenacaftor — ácido 8-metil-2-(3-metil-1-benzofuran-2-il)-5-[(1*R*)-1-(oxan-4-il)etoxi]quinolina-4-carboxílico

$C_{27}H_{27}NO_5$




pudexacianinii chloridum

pudexacianinium chloride — 3-(3-{[3-(cyclomaltoheptaos-2^{I}-*O*-yl)propyl]amino}-3-oxopropyl)-2-{(1*E*)-2-[(3*E*)-3-{(2*E*)-2-[3-(3-{[3-(cyclomaltoheptaos-2^{I}-*O*-yl)propyl]amino}-3-oxopropyl)-1,1-dimethyl-1,3-dihydro-2*H*-benzo[*e*]indol-2-ylidene]ethylidene}-2-methoxycyclohex-1-en-1-yl]ethen-1-yl}-1,1-dimethyl-1*H*-benzo[*e*]indol-3-ium chloride

chlorure de pudexacianinium — chlorure de 3-(3-{[3-(cyclomaltoheptaos-2^{I}-*O*-yl)propyl]amino}-3-oxopropyl)-2-{(1*E*)-2-[(3*E*)-3-{(2*E*)-2-[3-(3-{[3-(cyclomaltoheptaos-2^{I}-*O*-yl)propyl]amino}-3-oxopropyl)-1,1-diméthyl-1,3-dihydro-2*H*-benzo[*e*]indol-2-ylidène]éthylidène}-2-méthoxycyclohex-1-en-1-yl]éthèn-1-yl}-1,1-diméthyl-1*H*-benzo[*e*]indol-3-ium

cloruro de pudexacianinio — cloruro de 3-(3-{[3-(ciclomaltoheptaos-2^{I}-*O*-il)propil]amino}-3-oxopropil)-2-{(1*E*)-2-[(3*E*)-3-{(2*E*)-2-[3-(3-{[3-(ciclomaltoheptaos-2^{I}-*O*-il)propil]amino}-3-oxopropil)-1,1-dimetil-1,3-dihidro-2*H*-benzo[*e*]indol-2-ilideno]etilideno}-2-metoxiciclohex-1-en-1-il]eten-1-il}-1,1-dimetil-1*H*-benzo[*e*]indol-3-ium

$C_{135}H_{197}ClN_4O_{73}$



quavonlimabum #

quavonlimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-445) [VH (*Homo sapiens* IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (81.6%) -IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":227-227")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
quavonlimab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CTLA4 (protéine 4 associée aux lymphocytes T cytotoxiques, CD152)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-445) [VH (*Homo sapiens* IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), charnière 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (224-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (81.6%) -IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224":227-227")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
quavonlimab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CTLA4 (proteína 4 asociada a los linfocitos T citotóxicos, CD152)], anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-445) [VH (*Homo sapiens* IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), bisagra 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (224-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (81.6%) -IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224":227-227")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DNWMNWVRQA PGKGLEWLAQ  50
IRNKPYNYET YYSASVKGRF TISRDDSKNS VYLQMNSLKT EDTGVYYCTA 100
QFAYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRTSENIY GGLNWYQRKP GKSPKLLIYG  50
ATNLASGVSS RFSGSGSGTD YTLTISSLQP EDVATYYCQN VLRSPFTFGS 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-98	142-198	259-319	365-423
	22"-98"	142"-198"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (h 5-CL 126)	218-214'	218"-214'''		
Inter-H-H (h 11, h 14)	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:

H CHS K2:
445, 445"

ragifilimabum #

ragifilimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF18 (tumor necrosis factor receptor (TNFR) superfamily member 18, activation-inducible TNFR family receptor, AITR, glucocorticoid-induced TNFR-related, GITR, CD375)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-447) [VH (*Homo sapiens* IGHV1-2*02 (80.6%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS K>del (447)) (119-447)], (221-220')-disulfide with kappa light chain humanized (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (91.1%) -IGKJ2*01 (100%)) CDR-IMGT [12.3.9] (27-38.56-58.95-103) (1'-113') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (227-227":230-230")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
ragifilimab	immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF18 (membre 18 de la superfamille des récepteurs du TNF, récepteur de la famille TNFR induit par activation, AITR, récepteur apparenté au TNFR et induit par les glucocorticoïdes, GITR, CD375), anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-447) [VH (*Homo sapiens* IGHV1-2*02 (80.6%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (215) (119-216), charnière 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS K>del (447)) (119-447)], (221-220')-disulfure avec la chaîne légère kappa humanisée (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (91.1%) -IGKJ2*01 (100%)) CDR-IMGT [12.3.9] (27-38.56-58.95-103) (1'-113') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (227-227":230-230")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa